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“I draw from the absurd three consequences, which are my revolt, my freedom, and my 
passion.” 
The Myth of Sisyphus, Albert Camus 
i 
ABSTRACT 
The work presented in this thesis is an effort to decipher and understand the mechanism of 
action (MOA) of anticancer agents by building on and complementing chemical proteomics 
methods. The backbone of the thesis relies on a recent method called Functional Identification 
of Target by Expression Proteomics (FITExP) developed in Zubarev lab, where drug induced 
proteomic signatures are analyzed in various cell lines and top differentially regulated proteins 
with consistent behavior are determined, among which the drug target and mechanistic proteins 
are usually present. FITExP relies on the assumption that proteins most affected with a 
perturbation have a higher probability of being involved in that process. 
In this regard, Paper I aimed to enhance the performance of FITExP analysis by merging 
proteomic data from drug-treated matrix attached and detached cells. This is while the majority 
if not all proteomics and molecular biology experiments are performed in matrix attached cells, 
as the general belief is that detached cells lose their structural integrity and do not harbor 
valuable information. However, detached cells are those that are more sensitive to 
chemotherapeutics and might reflect the proteome changes better. The comparative proteomics 
of living and dying cells improved FITExP performance with regards to identification of targets 
and provided insight about proteins involved in cellular life and death decisions. Furthermore, 
the orthogonal partial least squares-discriminant analysis (OPLS-DA) paradigm presented in 
this study, was used throughout the thesis for contrasting and visualizing the proteomic 
signature of a molecule against others, to reveal targets and specific proteins changing in 
response to the molecule of interest. 
In Paper II, as a further development of FITExP and to demonstrate its applicability in a 
broader context, we built a proteome signature library of 56 clinical and experimental 
anticancer agents in A549 lung adenocarcinoma cell line. This resource called ProTargetMiner 
can be used for different purposes. The proximity of compounds in hierarchical clustering or t-
SNE could be used for prediction of the mechanism of new compounds. Contrasting each 
molecule against other treatments using the OPLS-DA scheme presented in Paper I, revealed 
drug targets, mechanistic proteins, resistance factors, drug metabolizing enzymes and effects 
on protein complexes. Representative examples were used to demonstrate that the specificity 
factors extracted from the OPLS-DA models can help identify subtle but biologically 
significant processes, even when such an effect is as low as 15% fold change. Furthermore, we 
showed that the inclusion of 8-10 contrasting molecules in the OPLS-DA models can produce 
enough specificity for drug target deconvolution, which offered a miniaturization opportunity. 
Therefore, we built three deeper datasets using 9 compounds that showed the most diverse 
proteome changes in the orthogonal space in three cell lines from major cancer types: A549 
lung, MCF-7 breast and RKO colon cancers. These datasets provide a unique depth of 7398, 
8735 and 8551 respectively, with no missing values. Subsequently, a Shiny package was 
created in R, which can employ these datasets as a resource and merge it with user data and 
provide OPLS-DA output and target deconvolution opportunity for new compounds. Finally, 
using the original ProTargetMiner data, we also built a first of its kind proteomic correlation 
database which can find applications in deciphering the function of uncharacterized proteins. 
Moreover, the resource helped to identify a set of core or untouchable proteins with stable 
expression across all the treatments, revealing essential functions within the cells. Such proteins 
could be used as house-keeping controls in molecular biology experiments. 
In paper III, we combined FITExP with other chemical proteomics tools Thermal Proteome 
Profiling (TPP) and multiplexed redox proteomics, to study the target and mechanism space of 
auranofin. This would also allow to assess the power, orthogonality and complementarity of 
these techniques in the realm of chemical proteomics. TPP is a recently developed technique 
that can monitor changes in the stability of proteins upon binding to small molecules. Redox 
proteomics is a method by which the oxidation level of protein cysteinome can be quantitatively 
analyzed. Auranofin is an FDA-approved anti-inflammatory drug for treatment of rheumatoid 
arthritis, but due to its potent antitumor activity, it is currently in clinical trials against cancer. 
Although several MOAs have been suggested for auranofin, uncertainties exist regarding its 
cellular targets; therefore, this molecule was chosen as a challenging candidate to test the 
chemical proteomics tools. A combination of the above mentioned tools confirmed thioredoxin 
reductase 1 (TXNRD1) (ranking 3rd) as the cognate target of auranofin and demonstrated that 
perturbation of oxidoreductase pathway is the main route of auranofin cytotoxicity. We next 
showed that changes in the redox state of specific cysteines can be linked to protein stability in 
TPP. Some of these cysteines were mapped to the active sites of redox-active enzymes. 
In Paper IV, using quantitative multiplexed proteomics, we helped to show that b-AP15, a bis-
benzylidine piperidone compound inhibiting deubiquitinases USP14 and UCHL5, produces a 
similar perturbation signature as bortezomib in colon cancer cells. However, in comparison 
with bortezomib, b-AP15 induces chaperone expression to a significantly higher level and leads 
to a more extensive accumulation of polyubiqutinated proteins. The polyubiqutinated proteins 
co-localize with mitochondrial membrane and subsequently reduce oxidative phosphorylation. 
These results help define the atypical cell death induced by b-AP15 and describe why this 
molecule is effective against apoptosis resistant cells in variety of tumor models.  
Finally, in Paper V, we extended the applications of TPP and combined it with specificity 
concept for proteome-wide discovery of specific protein substrates for enzymes. We developed 
a universal method called System-wide Identification of Enzyme Substrates by Thermal 
Analysis (SIESTA) that relies on the hypothesis that enzymatic post-translational modification 
of substrate proteins can potentially change their stability against thermal denaturation. 
Furthermore, we applied the concept of specificity similar to the above papers, to reveal 
potential substrates using OPLS-DA. SIESTA was applied to two enzyme systems, namely 
TXNRD1 and poly-(ADP-ribose) polymerase-10 (PARP10), identifying known and putative 
candidate substrates. A number of these candidate proteins were validated as PARP10 
substrates by targeted mass spectrometry, chemiluminescence and other assays. SIESTA is an 
unbiased and system wide approach and its broad application can improve our understanding 
of enzyme function in homeostasis and disease. In turn, specific protein substrates can serve as 
readouts in high throughput screening and facilitate drug discovery.   
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Taken together, in this thesis, FITExP methodology was improved in two directions. In paper 
I, we improved the performance of FITExP by combining the proteomics data from detached 
and attached cells. In Paper II, we demonstrated how the proteomics data on a multitude of 
drugs in a single cell line enables the discovery of compound targets and MOA. Furthermore, 
we built an R Shiny package which can serve as a resource for the cancer community in target 
and MOA deconvolution. In Papers III and IV, we applied an arsenal of chemical proteomics 
tools for characterization of two anticancer compounds. In Paper V, we expanded the 
applications of TPP to identification of specific protein substrates for enzymes in a system-
wide manner. 
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1 INTRODUCTION 
1.1 OF ANTICANCER DRUGS AND TARGETS: WHY PHENOTYPIC 
SCREENING? 
Despite advances in cancer diagnosis and therapy, International Agency for Research on 
Cancer projected 18.1 million new cases of cancer and 9.6 million deaths from cancer in 2018 
worldwide (Bray, Ferlay et al. 2018). Furthermore, although the total cancer death rate has 
dropped by 26% since 1991 till 2015, some types of cancers such as liver and brain have 
increased death rates (Siegel, Miller et al. 2018). With significant reduction in heart disease, 
according to WHO estimates in year 2015, in 91 of 172 countries studied, cancer has taken the 
first or second ranking as the leading cause of death and in an additional 22 countries, ranks 
third or fourth. 
Although some cancer types such as acute lymphoblastic leukemia (ALL) in children can be 
mostly treated (around 98% remission) (Vora, Goulden et al. 2013), some cancer types are 
irresponsive or resistant to the available treatments or are prone to relapse. Many if not most 
existing therapies only extend the patient lifespan by a limited time (Weigmann 2016). Taken 
together, drugs and methodologies aiming at cancer treatment and eradication are highly 
desired and sought for. 
For discovery and development of novel anticancer drugs, several paradigms exist, which 
mainly include targeted high throughput screening (Broach and Thorner 1996) and 
phenotyping screening (Moffat, Rudolph et al. 2014). On the contrary to targeted high 
throughput screening where a massive number of compounds are surveyed for binding to a 
given protein, in phenotypic screening, compounds inducing a certain biological effect are 
identified through cell-based assays. The other major advantage with phenotypic screening is 
that the chosen compounds are already bioactive, and have drug-like properties such as the 
potential to penetrate cell membrane (Moffat, Rudolph et al. 2014). Furthermore, the 
compounds are given a chance to induce the phenotype of interest by acting on multiple targets 
(Medina-Franco, Giulianotti et al. 2013), and therefore, they can in return, help identify novel 
drug targets, as “Determining the causal relationships between target inhibition and phenotypic 
effects may well open up new and unexpected avenues of cancer biology” (Moffat, Rudolph et 
al. 2014). The merits and disadvantages of each approach is summarized in Figure 1. Since 
these cell based screens are disease relevant and cover multiple targets in a single screening, 
they are believed to have higher success rates than the targeted approach. Statistically, during 
the period between years 1999-2008, compounds derived from phenotypic screening 
comprised about 37% of the first-in-class drugs approved by FDA, while targeted screening 
contributed 23%. However, targeted screening had a better success rate in follower drugs 
comprising 51% of approved drugs (vs. 18% from phenotypic screening) (Swinney and 
Anthony 2011; Lee, Uhlik et al. 2012). The higher success rate for the follower drugs is not 
surprising, since recognizing a feasible protein target facilitates the screening and drug 
development process. Although a recent study has noted a substantial increase in the approval 
of first-in-class drugs discovered by targeted screening covering the period of 2008-2013 (Eder, 
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Sedrani et al. 2014), phenotypic screening is still an essential and viable source of novel key 
compounds.  
Sophisticated and parallel analytical 
methods are usually required for 
deconvolution of the targets for 
molecules discovered in phenotypic 
screening and off-targets of those from 
high-throughput screening. Target and 
MOA deconvolution can be a time- and 
labor intensive process, if not even 
fruitless. These challenges have left many 
promising experimental compounds 
without a known MOA. Even among the FDA approved drugs, 7% have no known primary 
target, and around 18% lack a clear MOA (Gregori-Puigjané, Setola et al. 2012). In addition, 
some MOAs might have been wrongly associated with a number of molecules in the past 
(Somlyai, Collins et al. 2017) and off-targets are being identified on a routine basis (Klaeger, 
Gohlke et al. 2016; Van Esbroeck, Janssen et al. 2017). Thus, there is a huge unmet need for 
developing new methods for identification of the target and deconvolution of MOA in 
anticancer drug discovery and development (Schirle and Jenkins 2016). The majority of 
compounds act by binding and modulating the activity of target proteins; therefore, mass-
spectrometry based proteomics has become an indispensable tool in drug development (Schirle, 
Bantscheff et al. 2012). 
1.2 ADVANCES IN MASS-SPECTROMETRY BASED PROTEOMICS AND ITS 
UNIQUE APPLICATIONS 
Advances in mass spectrometry in the last decades have turned it into an unprecedented means 
to investigate the proteome (Aebersold and Mann 2003). Proteomics is now routinely used to 
study variations in protein abundances, modifications, stability and etc. between different 
conditions. The realm of applications will be vastly expanded even further with the advent of 
single cell proteomics (Budnik, Levy et al. 2018).  
Milestone studies have extended the proteome coverage captured by mass spectrometry. Over 
a three-year period from 2011, the number of detected proteins in a single LC-MS analysis 
improved from 3000 yeast proteins in 8 hours (Thakur, Geiger et al. 2011) to 4000 proteins in 
1.1 hours (Hebert, Richards et al. 2014). That significant improvement was mainly due to the 
introduction of new MS platforms with enhanced MS/MS acquisition rate as well as a higher 
resolution and mass accuracy. However, the advancements in sample preparation techniques, 
chromatographic separation, quantification algorithms and data processing also played a part. 
Currently, single-shot proteomics experiment can routinely sample half of the expressed 
mammalian cell proteome, i.e. exceeding 5,000 proteins (Pirmoradian, Budamgunta et al. 
Figure 1. The attributes of high-throughput vs.
phenotypic screening
High-throughput screening Phenotypic screening
Target-centric
Reductionist view
Validation in cell
based assays 
needed
Target-agnostic
Holistic view
Higher physiological 
relevance
Hits have drug-like
properties
Multiple targets might be 
engaged
Target identiﬁcation and
validation needed
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2013; Scheltema, Hauschild et al. 2014). Very recently, it has become possible to quantify 
10,000 proteins in 100 minutes, although special set-ups and specific high resolution mass 
spectrometers are required (Meier, Geyer et al. 2018).  
In parallel, various labeling technologies have made it possible to multiplex samples in a single 
analysis. Not only has this made direct comparison between the proteomes possible within the 
same LC-MS run, but it has also reduced the variation between experimental replicates. 
Labeling also provides an opportunity to fractionate the pooled samples to obtain higher 
proteome coverage. Orthogonal fractionation of a sample reduces the sample complexity, 
which allows one to take deeper snapshots of the proteome, reaching more than 10,000 proteins 
(Sabatier, Saei et al.) (paper not included in this thesis). Extensively used fractionation 
techniques include high pH reversed-phase chromatography (Batth, Francavilla et al. 2014) 
and isoelectric focusing (Branca, Orre et al. 2014; Pirmoradian, Astorga-Wells et al. 2015). 
As a result of these advances, proteomics is now routinely used in biomarker discovery (Zhan, 
Li et al. 2018), protein network analysis (Bennett, Rush et al. 2010; Tan, Go et al. 2018), cell 
type comparison (Gholami, Hahne et al. 2013), analysis of protein stability (Leuenberger, 
Ganscha et al. 2017; Becher, Andres-Pons et al. 2018; Dai, Zhao et al. 2018) and turnover 
(Savitski, Zinn et al. 2018), as well as investigation of post-translational modifications (PTMs) 
(Christophorou, Castelo-Branco et al. 2014; Weinert, Narita et al. 2018), proteoforms (Ntai, 
Fornelli et al. 2018) and proteogenomics (Zhu, Orre et al. 2018). Arguably, one the most 
important applications of mass spectrometry is drug target and MOA deconvolution, in line 
with the chemical proteomics paradigm (Savitski, Reinhard et al. 2014; Browne, Jiang et al. 
2018).  
A routine question from biologists is: “what can proteomics do in comparison with other high-
throughput technologies e.g. RNA sequencing?” There are inherent differences in the type of 
information obtained from proteomics compared to RNA sequencing. First and foremost, 
proteomics is the only system-wide tool that provides information on both protein production 
and degradation. Such information is not reflected in genomics or transcriptomics data. Several 
studies have shown that the global mRNA levels are not strongly correlated with protein 
abundances even under steady state (Edfors, Danielsson et al. 2016; Liu, Beyer et al. 2016). 
Furthermore, some particular proteomic applications exist that are by default not amenable to 
genomics and transcriptomics. For example, proteomics can be used to observe and quantify 
myriad of PTMs on proteins (Savitski, Nielsen et al. 2006; Chick, Kolippakkam et al. 2015). 
Metabolic labeling can be applied to quantify protein degradation, translation and overall 
turnover (Boisvert, Ahmad et al. 2012). Redox proteomics, on the other hand, utilizes cysteine 
labeling to quantify the oxidation state of the proteins (Checconi, Salzano et al. 2015). 
Hydrogen-deuterium exchange mass spectrometry (HDX-MS) can be employed to study the 
binding site of various molecules on proteins or to validate ligand-protein interactions (Visnes, 
Cázares-Körner et al. 2018). 
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A major recent development was combining Cellular Thermal Shift Assay (CETSA) (Molina, 
Jafari et al. 2013) with multiplexed proteomics to establish the TPP technique which is capable 
of proteome-wide monitoring of protein stability in response to different conditions or small 
molecule treatments in living cells (Savitski, Reinhard et al. 2014). Protein stability is thus a 
new dimension in proteomics, inaccessible to genomics and transcriptomics, which sparked 
new interest in studying protein thermal unfolding and structural parameters dictating thermal 
stability in different organisms (Leuenberger, Ganscha et al. 2017).  
Overall, such parameters as protein presence and abundance, sequence, stability, mutations 
(proteogenomics), PTM type and occupancy, protein degradation/turnover rate, oxidized-
reduced states, interactions, binding sites and even isotopic composition can be investigated by 
mass spectrometry. 
 
1.3 PROTEOMICS BASED DRUG TARGET DECONVOLUTION STRATEGIES 
Chemical proteomics can be used to study the relationship between the drug molecules and 
cellular phenotype (Kwon and Karuso 2018). Classically, chemical proteomics refers to mass 
spectrometry–based affinity chromatography approaches to identify the protein interactors of 
small molecules or probes in the system-wide scale (Rix and Superti-Furga 2009). Recently, 
chemical proteomics is extended to other techniques, where changes in the proteome state –
such as stability, expression, oxidation state and covalent modification, can be connected to the 
targets or functions of small molecules (Savitski, Reinhard et al. 2014; Chernobrovkin, Marin-
Vicente et al. 2015; Browne, Jiang et al. 2018; Piazza, Kochanowski et al. 2018). Although 
identification and characterization of the efficacy target, the protein through which the 
compound exerts the desired phenotype, is very challenging and at times fruitless (Kotz 2012), 
it is indeed of paramount importance. Characterization of target and MOA can help simplify 
the prediction of efficacy and side effects and later on contribute to optimization of the lead 
compound scaffold. In parallel, for already approved drugs with poorly known targets, drug 
target studies can facilitate the design of next generation compounds with reduced side effects 
and perhaps higher efficacy. Target characterization can also reduce the chance of failure 
during clinical trials, as many drug candidates fail due to lack of efficacy in humans (Bunnage, 
Gilbert et al. 2015).  
Taken together, unbiased techniques are required for uncovering drug target and MOA, 
especially those that exert a phenotype of interest. Several technologies exist for characterizing 
the direct and indirect target space of a given anticancer compound. Individual methodologies 
harbor different resolutions, strengths and weaknesses (Schirle and Jenkins 2016). Since these 
methods usually provide complementary information, it is imperative to use them in concert 
(Schenone, Dančík et al. 2013). In this section, we will only focus on drug target deconvolution 
strategies based on mass spectrometry. 
  5 
1.3.1 Small-molecule affinity proteomics 
Affinity based approaches were first introduced in the early 1950s and aimed to identify 
protein-binding spectrum of a molecule (Campbell, Luescher et al. 1951). Today, chemical 
proteomics encompasses mass spectrometry-based affinity chromatography approaches for 
identification of ligand-protein interactions in the whole proteome background. The first step 
in affinity purification for target identification is the modification of compound of interest with 
a linker and its subsequent immobilization on a solid support to produce a compound display. 
Subsequently, the immobilized drug is exposed to the protein of interest or the disease relevant 
cell lysate. After several wash steps to remove the non-binding proteins, the binders are 
digested and subjected to LC-MS analysis and the enriched interactors are identified. In this 
paradigm, the advantage of using a cell lysate over purified protein is that the reaction will take 
place with the specific proteoforms with natural sequences, PTMs and potential protein 
interactors which might be important in compound binding. A drawback of this technique is 
that direct and indirect targets cannot be differentiated, as accessory proteins interacting with 
the real target might also be enriched. Another downside of the lysate-based non-covalent 
affinity pulldown methods for identification of drug targets is the incompatibility of integral 
membrane proteins, as such proteins might lose their native binding conformation through the 
experimental workflow (Bassilana, Carlson et al. 2014; Akbulut, Gaunt et al. 2015).  
Since the linker should be attached on a permissive site to retain compound activity, the 
synthesis of these tool compounds can be challenging. For some compounds, it might even be 
impossible to introduce such a linker. To ensure that the compound is still specific after the 
modification, its activity must be investigated in comparison with the parent compound. 
Alternatively, photo-crosslinker matrices can be irradiated together with the parent compound 
to produce a random compound display, which can presumably include orientations compatible 
with target protein binding (Kanoh, Honda et al. 2005). Furthermore, assessing active and 
inactive probes sharing the same scaffold can help to identify the most phenotypically-relevant 
interactors (Oda, Owa et al. 2003). To rule out false interactions, competitive-binding 
experiment can be performed, in which the free probe competes with immobilized probe for 
binding to the target proteins. Affinity purification has been used to identify the complexes 
targeted by histone deacetylase inhibitors (Bantscheff, Hopf et al. 2011). Such a methodology 
has also been used to characterize oxysterol binding proteins as the cellular carriers of OSW-1 
-a highly potent natural anticancer lead compound, and to show that these proteins are essential 
for cell survival (Burgett, Poulsen et al. 2011). A miniaturized version of these affinity 
pulldowns has been optimized for profiling of the targets of clinical kinase inhibitors in tumor 
biopsies (Chamrád, Rix et al. 2013).  
On the contrary to non-covalent methods, covalent approaches can freeze the interaction of an 
affinity probe with its target. In this approach, a reactive group and an affinity handle (e.g. 
biotin) are conjugated to the compound. This strategy has been used for validation of Sec61a 
as a target of cyclodepsipeptide (MacKinnon, Garrison et al. 2007). Covalent approaches also 
allow for using denaturing conditions, since the preservation of protein binding conformation 
is not necessary. As the interactors are identified though proximity-driven labeling events, this 
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methodology can be used to eliminate indirect accessory proteins enriched with the target 
proteins in complexes. For example, while a non-covalent suberanilohydroxamic acid (SAHA, 
a class I/IIb HDAC active-site inhibitor) probe gave several HDAC-containing complexes as 
specific targets (Bantscheff, Hopf et al. 2011), the covalent SAHA–BPyne probe was more 
specific in finding core HDACs as direct binders (Salisbury and Cravatt 2007). The covalent 
approaches sometimes suffer from low affinity of interactions and low efficiency of labeling, 
which can be ameliorated by performing further assays such as competition with free 
compound or probe titration, to enhance the specificity of detected interactions. A challenge in 
the latter technique is its uncertain applicability to live cells and membrane fractions. 
Browne et al. recently developed a method called CITe-Id (Covalent Inhibitor Target site 
IDentification) for proteome-wide target-site identification of covalent inhibitors (Browne, 
Jiang et al. 2018). This chemoproteomic approach employs covalent inhibitors for enriching 
cysteine-thiols across the proteome, and therefore provides direct, amino acid level readout in 
a dose-response manner. Using this method, they discovered that PKN3 is covalently inhibited 
by JZ128. 
Kinobead technology for target profiling might also be classified as an affinity-based 
technique, but is based on a different methodology. In this method (Figure 2), broad spectrum 
kinase inhibitors or ATP mimetics are immobilized on beads and incubated with the lysate of 
interest. The addition of a desired kinase inhibitor (new compound) to the experiment, will 
compete with beads for binding to the present kinases. After 
capturing the tissue kinome on matrix, the enriched proteins 
are identified by proteomics (Bantscheff, Eberhard et al. 
2007). The kinobead methodology was recently applied to 
243 kinase inhibitors (Klaeger, Heinzlmeir et al. 2017). One 
of the limitations of this technology is that it currently does 
not apply to the full human kinome. Furthermore, the 
potential non-kinase targets of the compound are ignored. 
Moreover, since a priori knowledge about the compound –
being a kinase inhibitor is assumed, kinobead technology 
cannot be categorized as a target deconvolution strategy. 
Figure 2. Kinobead technology. Broad spectrum kinase inhibitors or 
ATP mimetics are immobilized on beads and incubated with the lysate. 
The added kinase inhibitor will compete with kinase binding to beads. 
After capturing the tissue kinome on matrix, the enriched proteins are 
identified by proteomics. A reduction of kinase binding to beads is a 
measure of compound binding to the respective kinase. Redrawn from 
(Klaeger, Heinzlmeir et al. 2017), with permission from The American 
Association for the Advancement of Science. 
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1.3.2 Functional expression based-approaches 
Chernobrovkin et al. developed a method in 2015, called Functional Identification of Target 
by Expression Proteomics (FITeXP) (Chernobrovkin, Marin-Vicente et al. 2015). FITExP is 
an expression proteomics-based strategy for deconvolution of potential drug targets and MOA. 
Unlike other methods, expression proteomics takes protein degradation into account, and it can 
prove highly useful for investigating drug target and MOA. In FITExP, at least three cell lines 
are treated with the test compound at LC50 concentrations for about two doubling times and 
subsequently, differentially expressed proteins with consistent behavior in all tested cell lines 
are deciphered (Figure 3). In brief, all proteins are sorted by their regulation upon treatment in 
different cell lines and the rankings are combined. To increase the specificity, and to filter out 
the generic and/or stochastically behaving proteins involved in cell death or detoxification, a 
few known drugs are added to the compound panel for contrast. A collateral advantage of 
FITExP is that co-regulated proteins with biggest abundance changes can be subjected to 
pathway analysis to characterize the compound MOA. Another advantage of FITExP is that 
chemical modification of the parent molecule is not necessary and no a priori knowledge about 
the drug MOA is required. Furthermore, FITExP allows for rank ordering of the putative 
targets. In the proof of principle experiments, FITExP could identify the target of several 
known small anticancer molecules among more than 4000 proteins (Chernobrovkin, Marin-
Vicente et al. 2015). Besides the analysis of the target and MOA of chemotherapeutics 
(Chernobrovkin, Marin-Vicente et al. 2015), FITExP has been also used to deconvolute the 
target and MOA of metallodrugs to help 
finding optimal drug combination (Lee, 
Chernobrovkin et al. 2017). The 
approach was also applied to 
nanoparticles to investigate their 
cytotoxic and pro-inflammatory effects 
(Tarasova, Gallud et al. 2016). 
The underlying principle in FITExP is based on the exceptional abundance change of the drug 
target and compound-specific mechanistic proteins upon treatment. Various phenomena can 
underlie the exceptional up-regulation (or in rare cases down-regulation) of the target protein 
in response to drug binding. First and perhaps the most important, are the feedback mechanisms 
Figure 3. FITExP methodology. A) At least three 
cell lines are treated at LC50 concentrations with 
a compound panel including the molecule of 
interest and B) the proteomes are analyzed. C) 
Proteins are ranked based on their fold change in 
different cell lines, culminating in a combined 
ranking. The top proteins are potential target 
candidates. D) The target protein profile for 
compound of interest (Drug 1 here) usually has a 
higher regulation in majority of cell lines. E) 
Finally, a list of top ranking proteins can be 
subjected to pathways analysis in StringDB or 
similar databases to reveal compound MOA.  −0.5
−1
0
0.5
1
C
lu
s
te
rs
Log (expression
2
vs. control)
Cell line 1
Cell line 2
Cell line 3
C
o
n
tr
o
l
D
ru
g
 1
D
ru
g
 2
D
ru
g
 3
E
x
p
re
s
s
io
n
1
Speciﬁcity
D
ru
g
 1
D
ru
g
 2
D
ru
g
 3
C
o
n
tr
o
l
Target protein proﬁle
Protein name
Protein A (Target)
Protein B
Protein C
Protein D
Protein E
Protein F
...
Ranking
1
2
3
4
5
6
...
Target identiﬁcation 
MOA characterization by 
pathway analysis
A
B
C
D
E
 8 
which induce the up-regulation of proteins with suppressed activity (Legewie, Herzel et al. 
2008). Second, drug binding can alter the stability of protein and accelerate or decelerate its 
turnover (Cohen, Geva-Zatorsky et al. 2008). Such feedback loops are not limited to higher 
organisms; for example, inhibition of the cholesterol pathway in yeast transcriptionally induces 
the expression of several genes in this pathway (Daum, Lees et al. 1998). Such level of protein 
expression control have also been observed in more primitive organisms (Smits, Kuipers et al. 
2006; Palmer and Kishony 2014). 
 
1.3.3 Discovery of covalent binders 
Proteomics might also be used for direct discovery of covalent protein-compound adducts. 
Such a strategy has been used to study covalent modifications of β-lactoglobulin A and human 
serum albumin by reactive metabolites from paracetamol, amodiaquine, and clozapine 
(Lohmann, Hayen et al. 2008). Furthermore, mass spectrometry has been used in a high-
throughput format to identify protein-inhibitor adducts for discovery of irreversible inhibitors 
(Campuzano, San Miguel et al. 2016).  
 
1.3.4 Methods based on target stability 
Stability is a new dimension in proteomics. A number of methods exist for monitoring protein 
stability changes upon ligand binding. An important advantage of these techniques, similar to 
expression proteomics based strategies such as FITExP, is that the modification of the parent 
compound is not required.  
One of the early stability-based methods called Pulse Proteolysis is based on the fact that urea-
induced unfolding enhances protein susceptibility to proteolysis. This feature can be exploited 
to monitor the level of protein unfolding in the presence and absence of a ligand, which can be 
detected by SDS-PAGE and mass spectrometry. In the proof-of-principle experiments, the 
authors showed the applicability of this method to confirm the binding of maltose and other 
cognate ligands to maltose-binding protein (Park and Marqusee 2005). 
The first technique that could be utilized for drug target identification in the whole proteome 
was drug affinity responsive target stability (DARTS) (Lomenick, Hao et al. 2009). The 
underlying concept in DARTS is that binding of a ligand can locally or globally stabilize the 
target protein, which can also be accompanied by covering protease recognition sites, and 
diminish the proteolysis of the target protein. This is highly similar to, for example, the 
resistance of transcription factor-bound DNA sites to DNAases (Maniatis and Ptashne 1973). 
In proof of principle studies, DARTS could confirm the binding of several molecules to their 
target proteins in the cell lysate background and establish proteins in translation machinery as 
targets for resveratrol. However, the applicability of DARTS for monitoring dynamic 
interactions in intact cells is yet to be proven.  
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A highly similar technique called Limited Proteolysis (LiP-MS) has been used to investigate 
the effects of metabolite binding on protein structure in Escherichia coli (Piazza, Kochanowski 
et al. 2018). This method relies on limited proteolytic digestion of proteins in the bound and 
unbound state and does not require the modification of small molecules. Although this method 
can only detect the conformational change of a fraction of the proteome and has never been 
applied to deconvolution of targets for drug molecules, it is envisioned that with further 
advances it can potentially find applications in such studies.  
Cellular Thermal Shift Assay (CETSA) was recently developed to monitor ligand binding to 
potential target proteins in living cells and lysate (Molina, Jafari et al. 2013). This methodology 
is using the well-established fact of the thermal stabilization (or occasional destabilization) of 
a target protein upon ligand binding, which results in a shift in the melting curve of the protein 
(Pantoliano, Petrella et al. 2001). CETSA experiments are performed in a Western blot format, 
in which antibodies are used to individually detect soluble protein content after heating cells to 
different temperatures and removing the aggregated proteins by centrifugation (Molina, Jafari 
et al. 2013). The advantage of CETSA over other target engagement methods is that it can be 
performed in living cells and tissues and as such, confirms the drug target engagement in a 
physiological context. Such aspect can be particularly important for drug metabolites or 
prodrugs that are activated after cellular entry. However, a priori knowledge about the target 
is needed and thus CETSA cannot be classified as a target deconvolution technique, but 
CETSA can still be used for screening. For example, CETSA screening was used to identify 
novel thymidylate synthase (TYMS) inhibitors from a compound library (Almqvist, Axelsson 
et al. 2016). 
More recently, Savitski et al. (Savitski, Reinhard et al. 2014) have coupled CETSA with 
quantitative multiplexed proteomics to study potential drug binding in the whole proteome, in 
a method called TPP. Since TPP measures the concentration of thousands of proteins 
simultaneously, it can also be used for drug target deconvolution. Different modes of TPP can 
be used to detect targets, off-targets and proteins which are affected down-stream of the target 
in the cells. In the TR-TPP (temperature range) experiments (Figure 4), TPP is performed in a 
fixed biologically relevant concentration of the compound over a temperature range. The 
readout is the melting point (Tm) of proteins and the shift in melting curves of a potential target 
protein between treatment and control (ΔTm). In most cases, TPP can identify the direct and 
indirect targets of a drug in live cells. In addition, TR-TPP experiments in cell lysate can help 
differentiate the proteins which are directly binding the compound, as the majority of 
downstream pathways are absent in the lysate. Furthermore, lysate experiments might also help 
to differentiate the compounds which engage their targets after metabolic transformation. 
Alternatively, CCR-TPP (compound concentration range) experiments, are performed at a 
fixed temperature (Tm of the target proteins) over a compound concentration range (Franken, 
Mathieson et al. 2015). The output of CCR-TPP is usually used to confirm the TR-TPP data, 
and the approach touches upon compound potency when comparing a panel of molecules 
within the same experiment (Franken, Mathieson et al. 2015).  
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Figure 4. TPP methodology. 
Living cells or lysate aliquots are 
heated step-wise within 37-67 °C, 
in the presence and absence of 
compound. Ultracentrifugation of 
the samples after heating leaves 
only the soluble non-aggregated 
fractions, which are multiplexed by 
TMT10 and quantitatively analyzed 
by mass spectrometry. The change 
in stability of a protein can be 
detected by tracking ΔTm. Reused 
from (Savitski, Reinhard et al. 
2014), with permission from The 
American Association for the 
Advancement of Science. 
A shortcoming of CETSA and TPP is that they are only applied to a) proteins soluble at normal 
conditions or non-denaturing buffers (this excludes, e.g., the majority of membrane proteins –
although this issue can be partially ameliorated with mild detergents (Reinhard, Eberhard et al. 
2015)), and b) proteins whose stability decreases with temperature. Also, the magnitude of shift 
in thermal stability is not predictable and is largely specific to the target protein and the binding 
event. Not all bindings lead to detectable changes in protein stability. Overall, these issues 
make the rank ordering of putative targets difficult.  
Very recently, a similar methodology, based on the same principles of thermal stability, has 
identified the target for small molecule compounds by in-gel fluorescence. The authors were 
able to identify and validate nucleophosmin as the target of hordenine, which is a natural 
compound known to up-regulate in vitro translation (Park, Ha et al. 2017). 
Despite the fact that TPP provides valuable information on protein state in a system wide level, 
low throughput and cost are major drawbacks of this technique, limiting its applications to labs 
specializing in mass spectrometry or core facilities. Our group recently developed a technique 
called Proteome Integral Stability Alteration (PISA) assay with 10x higher throughput, where 
TPP is reformatted by concatenation of the samples over the temperature range (Gaetani, 
Sabatier et al. 2018) (paper not included in this thesis). PISA circumvents the need to perform 
fitting of melting curves. The simplicity, lower expense and significantly higher throughput of 
PISA guarantee its widespread use in chemical biology and drug development. Furthermore, 
since samples are combined, PISA can be easily performed in multiple replicates (unlike TPP 
which is mostly performed in 2 replicates), allowing for more rigorous statistics. The rationale, 
schematics and workflow of PISA are shown in Figure 5. 
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Figure 5. Schematics of PISA. A) In PISA, individual samples heated to different temperature points are pooled, 
circumventing the need for curve fitting. B and C) ∆Sm can be easily calculated as the difference of the integral 
abundances of the protein between treated and untreated samples. D) Presentation of PISA results in a simple 
volcano plot allowing for a test of significance and highlighting potential targets of the compound. E) PISA 
workflow in living cells: incubation with compound, aliquoting, heating, freeze-thaw for lysing cells, pooling of 
samples, ultracentrifugation, collection of supernatant, digestion, TMT labeling, fractionation, high resolution LC-
MS/MS analysis, and subsequent data processing. Figure adapted with permission from (Gaetani, Sabatier et al. 
2018). 
1.3.5 Computational techniques and connectivity maps 
There have been several attempts to create computational in silico target identification 
methods, based on chemical similarity database searches and/or monitoring bioactivity 
fingerprint similarity. For example, Chemical Similarity Network Analysis Pulldown 
(CSNAP) is a computational drug target identification algorithm that exploits chemical 
similarity for recognition of chemotypes and identification of drug targets (Lo, Senese et al. 
2015). Using this method, the authors were able to identify novel compounds targeting 
microtubules.  
Reference genomic, transcriptomic, metabolomic and proteomic profiles can be potentially 
employed to discover functional connections among diseases, perturbations and drug action. 
Although proteomics databases are yet to be built, connectivity maps have already been created 
for gene expression signatures to connect small molecules sharing a MOA (Hughes, Marton et 
al. 2000; Lamb, Crawford et al. 2006; Rees, Seashore-Ludlow et al. 2016; Subramanian, 
Narayan et al. 2017; Readhead, Hartley et al. 2018; Ye, Ho et al. 2018). Such databases, in 
ideal case, must be able to cover all biological states that can be induced by chemical entities, 
in terms of genomic and/or proteomics profiles. Pattern-matching tools can be subsequently 
used to detect similarities among compound signatures. The assigned similarity scores can be 
used for rank ordering of the fingerprints. In a landmark study, such a gene expression database 
was built for 300 diverse mutations and chemical treatments in S. cerevisiae (Hughes, Marton 
1.0
0.5
6737 43 57
Temperature ( oC)
0.0
1.0
0.5
6737 43 57
Temperature ( oC)
0.0
2.0
1.0
0.0
R
el
at
iv
e 
ab
un
da
nc
e
 (a
rb
. u
ni
ts
)
Vehicle Compound
3.0
≥10 temperatures ORBITRAP FUSIONThermo
SCIENTIFIC
Frac 1
Frac n
Frac 2
0
1
2
-lo
g1
0(
p 
va
lu
e)
3 Potential targets
43 oC 57 oC
 E
ΔSm ΔSm
−0.4 0.0 0.4
ΔSm (arb. units)
+vehicle
+compound
Tre
at c
ells
Hea
t
[Fre
eze
 tha
w]
Ultr
a-c
ent
rifu
ge
Col
lect
 sup
ern
ata
nt
Poo
l
Dig
est
Lab
el w
ith T
MT
Fra
ctio
nat
e
a a
naly
sis
LC-
MS
/MS
Dat
B
N2
So
lu
bl
e 
fra
ct
io
n
So
lu
bl
e 
fra
ct
io
n
Sm
Sm’
C DA
12 
et al. 2000). The authors showed that the affected cellular pathways can be determined by 
pattern matching. Investigation of the gene expression profiles caused by deletion of 
uncharacterized genes led to functional annotation of eight previously uncharacterized open 
reading frames. Moreover, the authors could identify the dyclonine target.  
A similar attempt has led to the generation of commercial databases embedded with expression 
profiles from rat tissues upon systemic drug administration (Ganter, Tugendreich et al. 2005). 
This database, in 2005, had gene expression profiles for approximately 600 different 
compounds in 7 rat tissues (approximately 3200 different drug-dose-time-tissue combinations). 
In this study, combining the clinical pathology assessments with gene expression profiles could 
explain why carmustine, methotrexate, and thioguanine had similar effects on the 
hematopoietic tissues, while they induced diverse hepatotoxicity.  
Lamb et al. created the first connectivity map database in human cells (Lamb, Crawford et al. 
2006). They created a gene expression profile database of 164 distinct small-molecule 
perturbagens, representing diverse functions, including FDA–approved drugs and nondrug 
bioactive tool compounds. The database was used to show that drugs with similar MOA will 
have similar genomic fingerprints (Figure 6). They reported that drugs with similar MOAs 
(estrogen receptor modulators and genistein) showed positive connectivities, while an 
antagonist (fulvestrant) demonstrated negative connectivity. The dataset could also be used as 
a discovery tool, for example by identification of gedunin as an HSP90 inhibitor. Ever since, 
connectivity map has been successfully used for deconvolution of compound MOA (D'arcy, 
Brnjic et al. 2011), lead discovery (Hieronymus, Lamb et al. 2006) and drug repurposing 
(Sirota, Dudley et al. 2011). 
Figure 6. Connectivity map is a reference database of gene expression profiles built for hundreds of 
perturbagens in cultured human cells. A query gene expression signature (for a new compound) is scored for 
similarity/dissimilarity to/against each reference profile in the database using pattern matching algorithms. The 
‘‘connectivity score’’, as a measure of similarity, is used to rank the profiles that are connected to the query. Figure 
reused from (Lamb, Crawford et al. 2006), with permission from The American Association for the Advancement 
of Science. 
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Very recently, a new generation connectivity map (CMap-L1000v1) was introduced with 
400,000 signatures using the L1000 platform (Subramanian, Narayan et al. 2017). Since 
standard library construction with RNA sequencing of many compounds can be costly, 
miniaturized approaches are desired. L1000 is a strategy involving ligation-mediated 
amplification of 1,000 landmark transcripts followed by capturing the amplified products on 
fluorescently addressed microspheres (Peck, Crawford et al. 2006). The data on the 1,000 
landmark transcripts was used to computationally infer the expression level of non-measured 
transcripts. Since the new connectivity map is relatively new, its efficiency and applicability is 
yet to be determined.  
Ye et al. published another strategy called DRUG-seq (Digital RNA with pertUrbation of 
Genes) for miniaturized high-throughput transcriptome profiling that can be used in drug 
discovery (Ye, Ho et al. 2018). DRUG-seq reduces the cost of RNA sequencing by 100 fold. 
In the proof-of-concept experiments, the authors profiled the transcriptional changes of 433 
compounds across 8 doses. The transcriptional signatures could group the compounds into 
MOA clusters based on known targets. 
However, all connectivity map efforts have been based on gene expression (mRNA) profiles, 
despite the fact that the cellular levels of proteins often differ significantly from those of 
mRNAs (Edfors, Danielsson et al. 2016; Liu, Beyer et al. 2016). A major reason for the lack 
of proteomics connectivity maps is the cost and labor of the analysis with respect to the required 
depth, which can be significantly higher in proteomics. Only recently, a proteomics 
connectivity map was built comprising the phosphoproteomic and chromatin signatures, 
quantitating 100 phospho-peptides and 59 histone modifications for 90 drugs in 6 human cancer 
cell lines (Litichevskiy, Peckner et al. 2017). However, such signatures might be irrelevant for 
most compounds. Due to the fact that proteins are the factual functioning biological entities in 
the cells, and most drug targets are proteins, analyzing proteomes can furnish further 
information and be more specific to drug MOA. After all, the biological systems are defined 
by protein expression and degradation collectively (Li and Biggin 2015; Savitski, Zinn et al. 
2018). The balance between protein production and degradation is only reflected in proteomics 
data and cannot be assessed by genomics and transcriptomics in principle. Also, mRNA levels 
are not strongly correlated with protein concentrations even under steady state conditions 
(Edfors, Danielsson et al. 2016; Liu, Beyer et al. 2016), and this correlation must be even worse 
in dynamic situations, for example during programmed death, where many caspases-enhanced 
degradation pathways are activated (Nuñez, Benedict et al. 1998). Therefore, cataloging the 
proteomics fingerprints in response to a large number of diverse perturbations (compounds and 
treatments) can be the next step in building connectivity maps, by which drug targets and MOA 
of drugs can be studied in high detail, and new drugs can be characterized.  
It should be noted that any mechanistic prediction resulting from the above computer-based 
analyses such as connectivity maps and other pattern-matching tools is just that – a prediction. 
Such predictions must be tested and validated by follow-up experimental approaches. 
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Furthermore, a major issue with these tools is that all imaginable perturbations must be 
recorded to build an ideal system. This means that specific inhibitors of all cellular proteins 
must be profiled, which can be practically impossible. In majority of cases, these inhibitors do 
not exist or if so, they are unspecific. Another disadvantage is that a large perturbation database 
would make it difficult to interpret the results, as a multitude of perturbations might be scored 
as similar to the query signature. 
One of the main purposes of the current investigation was to build a proteomic signature 
resource of anticancer compounds to assess the feasibility of target and MOA deconvolution. 
We have tried to take a step back and rather focus on miniaturization, where a minimal number 
of experiments would be enough for overall assessment of compound MOA and identification 
of its potential targets. We consider this resource called ProTargetMiner, not a rival, but a 
complement for preceding drug target deconvolution databases such as connectivity maps. The 
modeling paradigm used in ProTargetMiner can be also employed in transcriptomics, as long 
as the biological endpoint used is identical, as in ProTargetMiner. 
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2 AIMS 
2.1 BROAD AIMS OF THE THESIS 
A major part of this project was devoted to further development of FITExP methodology and 
other chemical proteomics techniques. Subsequently, FITExP was coupled with other drug 
target deconvolution techniques such as TPP and redox proteomics to reveal the target and 
MOA of novel and interesting anticancer compounds. Where needed, complementary 
techniques were used to validate the findings of the above-mentioned techniques. 
We tried to further enhance the FITExP performance by inclusion of matrix-detached cells in 
the proteomics analysis (Saei, Sabatier et al. 2018). This is while previously in FITExP and the 
majority of molecular biology experiments, only matrix-attached cells were included and 
detached cells were usually ignored. 
The main building block of this project was on making a deep proteomic database of model 
major cancer cell line response to a library of FDA-approved drugs with known targets and 
MOA, as well as several novel anticancer compounds with unknown mechanisms. 
Features were adopted from original FITExP method (Chernobrovkin, Marin-Vicente et al. 
2015) to identify drug targets and deconvolute the MOA of the compounds in the 
library. The projection of proteome signatures in the multidimensional space or 
hierarchical clustering revealed the drugs which had similar gross mechanisms. OPLS-
DA methodology was used to determine compound-specific proteins. Furthermore, a 
public R shiny package was built for merging with user queries for novel compound.  
Along with building this database, we opted to apply chemical proteomics tools to investigate 
in detail the mechanism of interesting compounds auranofin and b-AP15. For this purpose TPP 
and FITExP were used in parallel. Redox proteomics as well as time and concentration series 
experiments were also used to further look in post-treatment proteome dynamics. 
Finally, we developed a method called System-wide Identification of Enzyme Substrates by 
Thermal Analysis (SIESTA) for extending the applications of TPP to discover novel specific 
protein substrates for enzymes. The underlying assumption in SIESTA is that the enzymatic 
post-translational modification of a substrate protein can change its stability profile. The 
substrates identified in SIESTA can serve as building blocks of high throughput screenings. 
2.2 SPECIFIC AIMS 
The specific aims of the current thesis, as presented in five scientific publications (Papers I-
V), are the following: 
• Objective 1 (Paper I): To finalize the development of a general proteomics-based method for
identification of targets and molecular processes triggered by anticancer treatments. 
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• Objective 3 (Paper II): To make a deep proteomic database of model cancer cell line response
to a library of FDA-approved anticancer library and novel anticancer compounds with 
unknown or complicated mechanisms. Develop tools to predict the target and the MOA of the 
compounds in the library. Finally, make a package by which user data can be merged and 
analyzed. 
• Objective 3 (Papers III and IV): To apply the developed method along with other available
target deconvolution strategies to a number of interesting anticancer compounds to unravel 
their targets, off-targets and cellular effects in detail.  
• Objective 4 (Paper V): To extend TPP for identifications of specific substrate proteins for
enzymes. As many enzyme are potential drug targets, information on specific protein substrates 
can be used to design and develop compound screening platforms for drug discovery. 
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3 METHODS 
3.1 CHEMICAL PROTEOMICS PARADIGMS 
Routine chemical proteomics methods used in the current thesis and their applicability areas 
have been covered in Figure 7. Apart from FITExP and TPP which were discussed in the 
introduction, other complementary methods such as redox proteomics as well as time- and 
concentration-series proteomics were used in this thesis to further dig into compound-induced 
cellular effects.  
3.2 LABEL FREE SAMPLE PREPARATION 
Label-free quantification is used to determine the relative amount of proteins in different 
samples and is thus mostly comparative. On the contrary to other protein quantification 
schemes, label-free strategy does not involve labeling of the proteins or peptides prior to 
quantification. In this approach, proteins are extracted, reduced with DTT, and subsequently 
alkylated with IAA. The proteins are then digested to peptides with specific enzymes such as 
trypsin and LysC, which are then cleaned and subjected to analysis (Figure 8). The classic 
label-free approach was used for all the experiments in Paper I, in FITExP experiment for 
auranofin (Paper III), and in the validation of ADP-ribosylation for SIESTA (Paper V).  
Figure 7. Complementary chemical 
proteomics strategies for deconvolution 
of targets and characterization of 
cellular downstream effects. While TPP 
provides information related to stability 
change of the target and downstream 
proteins, FITExP reveals disturbed 
cellular pathways and shortlists the target 
and mechanistic proteins. Redox 
proteomics reveals the changes in the 
oxidation state of cysteinome, which can 
correlate to stability change of the 
corresponding proteins in TPP. 
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Figure 8. Label-free scheme for sample preparation for LC-MS/MS analysis. 
3.3 TMT10 MULTIPLEXING 
TMT10 multiplexing was the main proteomics scheme used throughout this work. The protocol 
is similar to label-free technique till digestion. Afterwards, the peptides are labeled with amine-
reactive isobaric mass tags, pooled, cleaned and analyzed. TMT10 reagents consist of ten 
different isobaric labels with the same mass and chemical structure and are therefore 
isotopomeric (the general structure in shown in Figure 9A). Each tag has three constituents: 
amine-reactive NHS-ester group, a spacer arm and a mass reporter. In the mass reporter section, 
these labels contain a unique number and combination of 13C and 15N isotopes (TMT10 126-
131Da), and can therefore be measured in the low-mass region of a high-resolution MS/MS 
spectrum upon peptide fragmentation (Figure 9B). 
Figure 9. TMT10 labeling concept and workflow. A) Structural design of the TMT10 reagents. B) The relative 
abundance of peptide fragment in 10 different samples can be quantitated by comparing the reporter ion intensities 
which are generated by MS/MS fragmentation of the mass tags. C) Sample preparation with TMT10 multiplexing 
for LC-MS/MS analysis. HCD = higher-energy collisional dissociation and ETD = electron transfer dissociation. 
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Peptides from different samples are labeled with different tags, and therefore, the samples can 
be multiplexed and combined prior to analysis. Due to the multiplexed nature of samples, they 
can also be fractionated into peptide populations. This separation significantly simplifies the 
peptide mixture and enhances the proteome coverage captured by mass spectrometry. The 
overall workflow is given in Figure 9C. 
3.4 SEQUENTIAL IODOTMT LABELING FOR REDOX PROTEOMICS 
Within this thesis, redox proteomics was only applied in Paper III, where the changes in the 
redox state of proteins was measured in presence of auranofin in living cells. IodoTMT labels 
are currently six plex isobaric reagents which are used for covalent and irreversible labeling of 
sulfhydryl (—SH) groups. The concept is similar to TMT10, but he iodoTMT labels only react 
with reduced cysteines. The major application of these labels is in relative quantitation of 
cysteine modifications such as oxidation and disulfide bonds. In this approach, after extraction 
of cellular proteins, the already reduced cysteine are labeled with the first set of iodoTMT 
reagents and after reduction of disulfide bonds, the remaining cysteines are labeled with the 
second set of iodoTMT. The samples are then combined, digested, fractionated and subjected 
to mass spectrometry analysis (workflow in Figure 10). The oxidation of a peptide can thus be 
measured within the same sample by dividing the intensity of second label to the sum of the 
first and second label intensity.  
Figure 10. The redox proteomics workflow based on sequential labeling with iodoTMT reagents. 
3.5 PROTEOMICS 
All samples analyzed in this thesis were digested in solution. Proteins were reduced with DTT 
and then alkylated with IAA. Proteins were sequentially digested with LysC and trypsin. The 
obtained peptides were then cleaned using C18 columns. In experiments with TMT 
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multiplexing, the peptides were fractionated either using Pierce High pH Reversed-Phase 
Peptide Fractionation Kit (Thermo) or by a XBrigde BEH C18 2.1x150 mm column (Waters), 
using a Dionex Ultimate 3000 2DLC system (Thermo) for higher coverage (96 fractions 
concatenated to 16-24 based on the desired depth). 
 
3.6 LC-MS/MS 
Samples were loaded (in random order) with buffer A (0.1% formic acid (FA) in water) onto 
an EASY-Spray column (75 µm internal diameter, packed with PepMap C18, 2 µm beads, 100 
Å pore size, 50 cm) connected to either the EASY-nLC 1000 (Thermo; Cat#LC120) or to a 
nanoflow Dionex UltiMate 3000 UPLC system (Thermo) and eluted with a buffer B (98% 
ACN, 0.1% FA, 2% H2O) gradient from 2% to 26-35% of at a flow rate of 250-300 nL/min. 
Mass spectra were acquired with Orbitrap Elite, Orbitrap Q Exactive, Orbitrap Q Exactive Plus, 
Orbitrap HF or Fusion mass spectrometers (Thermo) in the data-dependent mode (various 
instruments were used in different studies and details can be found in relevant papers). Peptide 
fragmentation was mostly performed via higher-energy collision dissociation (HCD) with 
energy set at 33-35 NCE.  
 
3.7 QUANTIFICATION 
The raw data from LC-MS were analyzed by MaxQuant (Cox and Mann 2008) in all the papers. 
The Andromeda engine (Cox, Neuhauser et al. 2011) searched MS/MS data against Uniprot 
complete proteome database. Cysteine carbamidomethylation was set as a fixed modification, 
and methionine oxidation was used as a variable modification. Trypsin/P was selected as the 
enzyme and less than two missed cleavages were allowed. A 1% false discovery rate (FDR) 
was applied to filter the results at both protein and peptide levels. Match between runs was 
enabled in all the analyses, when applicable. Default settings were used for all the other 
parameters.  
In Paper V, for identification of ADP-ribosylation, mass spectra were converted to Mascot 
generic format (MGF) files using in-house written RAWtoMGF v. 2.1.3 package. The resulting 
MGFs files were searched against the UniProtKB human database (v. 201806) including 
71,434 sequences. Mascot 2.5.1 (Matrix Science) was used for identification of peptide 
sequences. Enzyme specificity was set to trypsin, and only two missed cleavages or less were 
allowed. ADP-ribosylation of C, D, E, K, N, R and S residues as well as methionine oxidation 
were chosen as the variable modification, while carbamidomethylation was set as a fixed 
modification on cysteine. 
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3.8 DATA ANALYSIS 
After removing all the contaminants, only proteins with at least two peptides were included in 
the final datasets in all the studies. Proteins with missing values were ignored in most of the 
analyses. Protein abundances were normalized by the total protein abundance (total intensity) 
in each sample. For multidimensional data analysis, a second normalization was performed by 
average protein abundance in different samples. Data were processed by Excel, R, Python, and 
SIMCA (Version 15, UMetrics, Sweden). All reported p values throughout the studies were 
from two sided student t-test.   
OPLS-DA models were used throughout this thesis and were built either in SIMCA 14-15 or 
R. OPLS-DA method allows for supervised grouping of the compounds before analysis. Using
these model, the signature of a given compound or set of compounds can be contrasted against 
the other molecules in the dataset. In these models, the compound-induced specifically up- or 
down-regulated proteins can be found on the extremities of the loading plot, where each protein 
is represented by a dot. All the other components are cast off to the second dimension. A tutorial 
example is detailed in Figure 11. 
Figure 11. OPLS-DA modeling scheme. The proteomic signature of the compound (or any other perturbation) 
of interest (CLASS I) is contrasted against those of all other compounds (or a desired subset of compounds) 
(CLASS II). Proteins are represented by gray dots on the plot. Proteins on the right and left extremities of the x 
axis are most specifically up- and down-regulated proteins, respectively. Note that besides the magnitude of 
the effect, OPLS-DA takes reproducibility (significance) into account. Therefore, even proteins with 
minimal but reproducible changes can be identified using this strategy. Figure reused with permission 
from (Saei, Chernobrovkin et al. 2018). 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I. COMPARATIVE PROTEOMICS OF DYING AND SURVIVING 
CANCER CELLS IMPROVES THE IDENTIFICATION OF DRUG TARGETS 
AND SHEDS LIGHT ON CELL LIFE/DEATH DECISIONS 
 
In Paper I, we focused on improving FITExP by inclusion of proteomics data obtained from 
matrix-detached cells in the analyses. Chemotherapeutics usually cause the detachment of 
adherent cancer cells, culminating in cell death. The original FITExP methodology and most 
molecular biology studies are based on the proteomic analysis of only matrix-attached cells 
after treatment and usually ignore matrix-detached cells. We hypothesized that since detached 
cells are more sensitive, they might reflect the chemotherapeutic-induced proteome changes in 
a better way. Furthermore, the proteomes of detached cells would possibly provide additional 
information on cell life and death decisions as well as sensitivity or resistance mechanisms to 
anticancer compounds. To test these hypotheses, we treated HCT-116, A375 and RKO cells 
for 48 h with 5-fluorouracil, methotrexate and paclitaxel and separately analyzed the proteomes 
of attached and detached cells.  
Interestingly, the most obvious finding was that the proteomes of detached cells showed a 
higher dispersity than attached cells in the principal component analysis (PCA) (Figure 12), 
indicating that the extent of proteome change during cell death is higher than even cell type or 
the applied treatments. The bottom-line of such an observation could be that life exist within 
specific proteome boundaries and harsh distortion of the proteome space can lead to cell death.  
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Figure 12. PCA of the whole proteome dataset of attached and detached cells (Q2 = 0.705). A) The first 
component separated the different states based on their attachment status, while the second component separated 
the tested cell lines. B) The third component apparently separated the proteomes based on carbohydrate metabolic 
parameters. Reused from (Saei, Sabatier et al. 2018) with permission from American Society for Biochemistry 
and Biophysics. 
The separate proteomics datasets on attached and detached cells performed comparably 
in target and drug MOA deconvolution, and when used in combination improved the target 
ranking for paclitaxel significantly and for 5-fluorouracil marginally. 
To discover proteins that specifically respond to a treatment of interest, we borrowed 
the specificity concept from FITExP method (Chernobrovkin, Marin-Vicente et al. 
2015). It is known that the molecular components of a pathway targeted by a compound 
present differential regulation. However, simple differential regulation (ratio of protein 
abundances in cell treated with drug divided by vehicle control) is not an efficient 
way to approach drug target deconvolution, as similar generic effects such as stress 
response, detoxification or death pathways can be triggered by different molecules. 
Therefore, we introduced specific regulation as: “the ratio of protein regulation in response 
to the drug of interest, to the median regulation in all other drugs or treatments in the 
library” (Chernobrovkin, Marin-Vicente et al. 2015). This approach can thus highlight the 
proteins that are specifically responding to a particular molecule. Although specificity 
values can be easily calculated, for visualization purposes, we also employ a 
sophisticated supervised classification method called OPLS-DA for characterization 
of specific proteins (Bylesjö, Rantalainen et al. 2006).
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Since these models were very useful in visualization of proteome responses, they were 
used throughout the whole project. OPLS-DA models were therefore built for the 
compounds in the study and their targets could be identified in top positions (Figure 13). 
Figure 13. OPLS-DA loading enables the (discovery and) visualization of drug targets and mechanistic 
proteins in FITExP. OPLS-DA loadings for A) methotrexate, B) 5-fluorouracil and C) paclitaxel vs. all other 
states in different cell lines. The drug targets and other proteins directly involved in drug MOA are shown in red. 
Adapted from (Saei, Sabatier et al. 2018) with permission from American Society for Biochemistry and 
Biophysics. 
We further analyzed the data to potentially discover features differentiating life from death in 
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regulation in either class, regardless of the cell line or the drug used. Six proteins consistently 
up- or down-regulated in the attached vs. detached cells were selected (a representative 
example has been shown in Figure 14) and knocked down each by two specific (functionally 
verified or predesigned) siRNAs in the presence and absence of compounds to decipher their 
roles in cell death/survival. The rationale and workflow of the siRNA experiments in 
summarized in Figure 15A-B and the results of siRNA experiments in three cell lines in 
presence and absence of the test compounds is given in Figure 15C. 
Figure 14. EIF4H as a representative 
protein which is down-regulated in 
all types of dying treated cells with all 
the treatments. Error bars not 
available for detached AF and HF, as 
EIF4H was not quantified in 1-2 
replicates (H = HCT116 cells, A = 
A375 cells, R = RKO cells, F = 5-
fluorouracil, M = methotrexate and P = 
paclitaxel). Reused from (Saei, 
Sabatier et al. 2018) with permission 
from American Society for 
Biochemistry and Biophysics. 
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Figure 15. The rationale and design of follow-up siRNA experiments. A) The rationale and methodology for 
selection of 6 proteins potentially differentiating cell death vs. survival. B) siRNA experiments workflow for 
functional validation. C) The effect of different siRNA knockdowns on the viability of cells in the presence or 
absence of compounds. Silencing CTTN, USP11, ACAA2 and EIF4H did not affect the cell viability in the 
presence of drugs (error bars represent the SD in 4 replicates). Reused from (Saei, Sabatier et al. 2018) with 
permission from American Society for Biochemistry and Biophysics.  
Conclusions 
In summary, this study showed for the first time, that on the contrary to the common line of 
thought, the proteomes of matrix-detached cells can be studied. As shown in this work, the 
transition to cell death had a larger impact on cell proteome than different cell type or changes 
exerted by anticancer compounds. It was shown that data from matrix-detached cells are a 
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valuable companion to attached cells in studying drug target behavior and MOA. The study 
also led to the discovery of proteins characteristic of cell death or survival irrespective of the 
cell line and type of treatment. Some of these proteins could be potential drug 
targets. 
However, there are a number of inherent limitations. This method can only be applied 
to adherent cells. Moreover, although this approach provides more information, it also 
doubles the number of samples in comparison with classic FITExP. Finally, some 
anticancer agents or treatments might disrupt the integrity of cell membrane and cannot 
be studied through this method.  
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4.2 PAPER II. PROTARGETMINER: A PROTEOME SIGNATURE LIBRARY OF 
ANTICANCER MOLECULES FOR FUNCTIONAL DISCOVERY 
As a further development of FITExP method, we built a publicly available expandable 
proteome signature library of anticancer molecules in A549 adenocarcinoma cells, called 
ProTargetMiner. The objectives of this study was to demonstrate the general applicability of 
FITExP methodology for different classes of compounds and to provide a public platform 
where the MOA of new compounds can be analyzed at the protein level. The main objective 
of ProTargetMiner is depicted in Figure 16. This resource contains the data on 287 proteome 
signatures for 56 compounds. The main dataset contains 7,328 proteins and 1,307,859 refined 
protein-drug data points.  
Figure 16. Objectives of ProTargetMiner. A) ProTargetMiner task, among other things, is to identify 
compounds with similar MOA in multidimensional space and provide specific information on drug targets, and 
protein involved in the cellular processes connected to the compound under study. B) The basic assumption is that 
drug targets and mechanistic proteins are specifically regulated. C) Compound-specific targets and proteins are 
pulled out using OPLS-DA-enabled specificity analysis. Figure adapted with permission from (Saei, 
Chernobrovkin et al. 2018). 
4.2.1 Construction of ProTargetMiner 
For the original dataset comprising 56 molecules, human A549 lung cancer cells were used as 
a model system for two reasons. First, A549 is a popular cell line harboring wild-type p53 and 
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is extensively characterized in the literature; and second, in the viability experiments this cell 
line showed a higher sensitivity to the compound library than the MCF-7 and RKO cells. The 
compound library comprised of 118 molecules cherry picked for cancer indication from 
Selleckchem FDA-approved drug library. Having compounds with known targets and MOAs 
was a prerequisite to successful establishment and benchmarking of the ProTargetMiner 
methodology. Filtered by sensitivity, 56 compounds were finally chosen (plus some 
compounds from collaborators with undefined or less defined targets or MOAs). The 
compounds grossly belonged to 19 different classes with versatile targets (112 known targets 
in total) and mechanisms, according to available information curated from DrugBank 
(https://www.drugbank.ca/) in January 2019. For each molecule, a concentration was used 
killing 50% of the cells (LC50) after 48 h and the respective proteomes were analyzed in at 
least three replicates. Methotrexate, paclitaxel, and camptothecin were included in each 
multiplexed experiment for normalization and quality control purposes (ProTargetMiner 
workflow in Figure 17). 
Figure 17. ProTargetMiner workflow. LC50 values were determined for the compound library (n=118) plus 
some other compounds in three cell lines; A549 cells were chosen based on their higher sensitivity; compounds 
were selected based on their cytotoxicity; cells were treated with 56 compounds and samples were prepared for 
shotgun proteomics in at least three independent biological replicates; samples were multiplexed in each 
experiment (methotrexate, paclitaxel and camptothecin were included in all 9 experiments); samples were lysed, 
digested, and labeled with TMT-10plex; pooled within each experiment and fractionated to increase the proteome 
coverage; individual fractions were analyzed by LC-MS/MS, followed by protein identification, quantification 
and data post-processing. Figure reused with permission from (Saei, Chernobrovkin et al. 2018). 
Having an identical biological endpoint (here 50% cytotoxicity) was essential, as it would make 
the comparison of the proteome signatures possible. Any differences in proteome signatures 
was thus related to dissimilarities in targets, MOA and cell death. Therefore, a special attribute 
of ProTargetMiner vs. connectivity map efforts, is the normalization of the biological endpoint. 
In other connectivity map efforts, fixed or random concentrations of compounds have been 
used which might not be biologically relevant.  
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4.2.2 Proteomic dissection of cell death trajectories 
It is known that compound signatures can be successfully separated by mapping the whole 
proteome or using even a subset of 1000 most abundant proteins (Chernobrovkin and Zubarev 
2016). Since the ProTargetMiner library is composed of >50 molecules with diverse MOA, it 
can potentially probe most cell death pathways. We would like to envision that these pathways 
are represented by cell death trajectories in the proteome space, which encompasses all possible 
cell states. We define cell death trajectory as a track in the proteome space, which is caused by 
a cytotoxic agent and passes from a normal living state to a death state (Saei, Chernobrovkin 
et al. 2018). The proteome space and death trajectories are shown in schematics in Figure 16. 
In the cell death community, there is a long-term debate and controversy on the number, nature 
and the molecular characteristics of cell death modalities (Galluzzi, Bravo-San Pedro et al. 
2015). For approaching this problem statistically with proteomics, we set to determine the 
number of orthogonal dimensions in the dataset. At least 11 independent dimensions were 
discovered in the original ProTargetMiner dataset using factor analysis. Cyclin-dependent 
kinase inhibitor 1 (CDKN1A) and PCNA-associated factor (PCLAF) were the most 
contributing proteins with opposite signs to the first dimension. Interestingly, CDKN1A plays 
a role in p53 mediated suppression of cell proliferation (Harper, Adami et al. 1993), and 
PCLAF is a cell cycle-regulated protein that regulates DNA repair (Emanuele, Ciccia et al. 
2011). The top 30 proteins of the first three dimensions mapped to “p53 signaling pathway and 
cell cycle”, “focal adhesion and angiogenesis” and “chromatin assembly and fatty acid 
metabolism”. The dimensions discovered in this dataset represent cell death trajectories as 
orthogonal pathways, or in other words theoretical constructs, and some of them might have 
little or no resemblance to the classical death modalities from textbooks (Zubarev, Nielsen et 
al. 2008). Expectedly though, some dimensions already corresponded to classic cell death 
modes, such as dimension 1 (p53-dependent apoptosis), dimension 4 (autophagy), and 
dimension 6 (macromitophagy). However, the other dimensions were hard to assign to known 
death modalities. Attributing the top proteins defining each dimension with the classic or novel 
cell death modalities can be an interesting subject for future research. Therefore, these 
dimensions and at least their top contributing proteins deserve detailed follow-up 
bioinformatics analysis and experimental validation.  
 
4.2.3 Similar compounds produce similar proteome signatures 
The nonlinear dimension reduction method t-SNE was used for dimension reduction of the data 
(Maaten and Hinton 2008). On this t-SNE plot that we call “death map”, all compound 
proteome signatures are projected as points. The proximity of signatures on this plot can be 
used to assess compound similarities. The compounds grouped by their proteomic signatures 
into expected clusters based on known targets and MOAs (Figure 18). As anticipated, well-
known compounds with similar MOAs (e.g., tubulin depolymerization inhibitors, pyrimidine 
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analogues, thioredoxin reductase inhibitors auranofin, TRi-1 and TRi-2 (Stafford, Peng et al. 
2018) and topoisomerase inhibitors) were close on the t-SNE plot.  
Figure 18. Drugs with similar MOAs have similar proteomics fingerprints and were mostly adjacent on the 
t-SNE plot (“death map”). Compound classes are shown with different colors. Figure reused with permission
from (Saei, Chernobrovkin et al. 2018).
Since tomatine was an obvious outlier in t-SNE and PCA, its data was not included in the 
following analyses. The extraordinary proteome changes in response to tomatine happen in 
both directions (up- and down-regulation) and are likely associated with proteasome inhibition 
(da Silva, Andrade et al. 2017) and unspecific membrane damage (Roddick and Drysdale 
1984), as reported before.  
Hierarchical clustering was also used to separate the compounds into clusters. As shown in 
Figure 19, the compounds were mostly separated in mechanistic clusters based on known 
targets/MOAs. Compounds known to directly or indirectly induce DNA damage were 
separated from the rest of the molecules. Tubulin inhibitors paclitaxel, docetaxel, vincristine 
and 2-methoxyestradiol, proteasome inhibitors b-AP15 and bortezomib, as well as thioredoxin 
reductase inhibitors TRi-1 and TRi-2, grouped together, indirectly validating the approach. The 
proteins in each cluster were subjected to GO enrichment. Interestingly, some of these clusters 
map to high density protein networks. For example, cluster 13 mapped to ribosome. Four 
compounds showed down-regulation of the ribosomal proteins, which is an indicator of 
ribosomal stress. Three of those molecules were pyrimidine analogues 5-fluorouracil, 
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floxuridine and carmofur. Therefore, floxuridine and carmofur potentially induce ribosomal 
stress, similar to 5-fluorouracil (Marin-Vicente, Lyutvinskiy et al. 2013). The fourth compound 
was an alkylating agent oxaliplatin. A recent paper actually showed that oxaliplatin mechanism 
is peculiar and not similar to other platinum analogues and that it involves induction of 
ribosome biogenesis stress (Bruno, Liu et al. 2017). Cluster 12 mapped to pathways related to 
protein folding and mainly shows up-regulation with proteasome inhibitors bortezomib and b-
AP15. Interestingly, a number of compounds particularly kinase inhibitors such as lapatinib, 
bosutinib and gefitinib showed an up-regulation of (chole)sterol synthesis pathways in cluster 
14. 
Figure 19. Hierarchical clustering separates the compounds into mechanistic clusters (compound classes are 
highlighted with colors; for simplicity of coloring, the compound classes affecting the same targets are grouped 
together). Compounds with similar well-known mechanisms mostly grouped together (left panel). Proteins in each 
cluster were subjected to pathway analysis and the corresponding three top enriched gene ontology (GO), 
molecular function (MF) or cellular component (CC) are shown. Cluster 9 did not map to any specific pathways.  
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4.2.4 Functional discovery in a compendium of proteome signatures 
As shown in Figure 19, there are specific features for every compound that must be pulled out 
using statistical approaches. We employed OPLS-DA modeling scheme presented in Paper I 
to identify specifically regulated proteins, among which drug target and mechanistic proteins 
are found. In the original FITExP method and Paper I, a panel of cell lines and a number of 
contrasting compounds were used to increase the specificity for deconvolution of targets and 
mechanistic proteins. The hypothesis of Paper II was to investigate if an equivalent increase 
in specificity can be achieved by a multitude of contrasting compounds in a single cell line. 
This would dramatically facilitate the applicability of the method for characterization of novel 
compounds. Therefore, we built OPLS-DA models for every molecule in this study, contrasting 
its proteome signature (class I) against all the other compounds (class II). OPLS-DA model 
loadings for methotrexate, paclitaxel, and vincristine show the deconvolution of cognate targets 
in Figure 20A-C. DHFR was found as a straightforward target for methotrexate. Paclitaxel and 
vincristine affect tubulin depolymerization and polymerization, respectively. Tubulins could 
be found among top-regulated proteins for both compounds. 30 top specifically regulated 
proteins close to x axis extremities were submitted to StringDB and the enriched pathways are 
shown in the right panel in Figure 20. These pathways reflect the known MOAs for the 
corresponding compounds.  
The OPLS-DA models also revealed compound effects on protein complexes. For example, 
for bortezomib, which is a proteasome inhibitor, specific up-regulation of proteasome subunits 
was noted (Figure 20D). The average fold change of proteasome subunits was 1.15 vs. control. 
Not only this shows the efficiency of OPLS-DA in pulling out subtle effects, but it also shows 
how a small perturbation in proteasome expression can have deleterious consequences for the 
cell. Likewise in sorafenib model (Figure 20E), NADH dehydrogenases and mitochondrial 
ribosomal proteins were specifically down-regulated, validating previous findings in human 
neuroblastoma cells (Bull, Rajalingam et al. 2012). These results demonstrate that 
ProTargetMiner results can also be carefully generalized to other cell lines.  
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Figure 20. ProTargetMiner reveals the targets, MOA and affected cellular complexes. A-E) 
Exemplary OPLS-DA model loadings for several compounds show the successful deconvolution of targets and 
MOA. The results of pathway analysis for the 30 top specifically up- or down-regulated proteins is shown on 
the right panel: KEGG pathways for methotrexate - “one carbon pool by folate and pyrimidine 
metabolism”; paclitaxel and vincristine - “tubulin”; bortezomib - “proteasome”. GO terms for sorafenib - 
“NADH dehydrogenase activity” (in red) and “mitochondrial translation” (in blue) (all p values < 0.001). RPL 
= ribosomal proteins of the large and RPS = ribosomal proteins of the small subunit. MRP = 
mitochondrial ribosomal proteins, ND = NADH dehydrogenase. Disconnected proteins not involved 
in the pathway has been omitted. Figure adapted with permission from (Saei, Chernobrovkin et al. 2018). 
4.2.5 The degree of drug-induced proteome changes 
The next hypothesis was if the extent of proteome perturbation can be associated with the 
specificity of the compounds (the number of affected targets and MOAs). Therefore, we ranked 
all compounds by the global deviation of their proteome signatures from control (Figure 21). 
As expected, proteasome inhibitors were among the compound inducing the largest deviations. 
The largest proteome deviation was induced by bortezomib, while on the other side of the 
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spectrum, tubulin inhibitors caused the smallest proteome perturbation. While the large 
proteome deviation can be the result of protein accumulation upon inhibition of the proteasome, 
the small perturbation of the proteome with tubulin inhibitors at LC50 concentrations, 
potentially indicates the high specificity and a lack of off-target effects for the latter. 
Furthermore, the slightest proteome change induced by dasatinib is unexpected, as this drug 
has 23 annotated targets in DrugBank as of January 2019. There was no particular correlation 
between compound LC50 and the extent of proteome changes. 
Figure 21. The extent of proteome deviation in response to each molecule, might be an indicator of 
compound specificity. Center line, median; box limits contain 50%; upper and lower quartiles, 75% and 25%; 
maximum, greatest value excluding outliers; minimum, least value excluding outliers; outliers, more than 1.5 times 
of upper and lower quantiles. Figure reused with permission from (Saei, Chernobrovkin et al. 2018). 
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4.2.6 Assessing the miniaturization possibility of ProTargetMiner concept 
Connectivity map efforts aim to saturate the mechanistic space by profiling myriad of 
compounds (Subramanian, Narayan et al. 2017). There are certain inherent limitations to these 
approaches. First, this would be an open-end project, as inhibitors of every cellular protein is 
not available. Even if inhibitors were available, most would be multi-targeted and unspecific. 
Second, the results of a connectivity map is a ranking of perturbations, which if too many would 
hamper the interpretation of results.  
Furthermore, in drug discovery and development, a detailed characterization of target and 
mechanism space, especially at the proteome level is desirable. Compound-induced effects are 
most advantageous if obtained in the most relevant biological models and cell types. However, 
building databases such as ProTargetMiner can be time-consuming, expensive and therefore 
not rational, at least not with the current technological platforms. Therefore, we tested if 
ProTargetMiner methodology could be miniaturized to a minimal compound panel size for 
effective deconvolution of drug targets and MOA. To obtain the optimal number of contrasting 
molecule needed for effective target and MOA characterization, we built PLS-DA models in 
R by using only a subset of contrasting compounds in the model (n = 1-54, 50 molecule 
combinations randomized for each n). In each iteration, the ranking of known targets for 
representative molecules camptothecin (target: TOP1), paclitaxel (target: tubulins), 
methotrexate (target: DHFR) and OSW-1 (target: OSBP1) and was calculated and the mean 
ranking for each n was obtained. As expected, the deconvolution process was more efficient 
with higher number of contrasting compounds (and not for randomly chosen non-target 
proteins) (Figure 22). Encouragingly, 8-10 contrasting signatures were already efficient for 
obtaining target rankings below 10.  
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Figure 22. Assessing the miniaturization possibility of ProTargetMiner concept by calculating the optimal 
number of contrasting molecules. PLS-DA models were built in R for 4 representative compounds, where they 
were contrasted vs. 50 random combinations of 1-54 compounds and the drug target ranking was averaged for 
each number. NDUFV2 and CARS2 proteins were randomly selected as non-target proteins. Figure reused with 
permission from (Saei, Chernobrovkin et al. 2018). 
4.2.7 Miniaturization of ProTargetMiner 
With miniaturization opportunity at hand, we decided to make ultra-deep proteomic databases 
in three extensively used cancer cell lines, A549, MCF-7 and RKO, for 9 molecules 
representing most diverse MOAs for providing optimal contrast. These datasets could then be 
merged with external data from users interested in target deconvolution for their compounds. 
These 9 molecules were chosen from different orthogonal dimensions in the factor analysis of 
the original ProTargetMiner dataset with 56 compounds, and include 8-azaguanine (target: 
PNP), raltitrexed (target: TYMS), topotecan (target: TOP1), floxuridine (target: TYMS), nutlin 
(target: MDM2), dasatinib (target: at least 23 kinase targets), gefitinib (target: EGFR), 
vincristine (target: tubulin) and bortezomib (proteasome). 
These deep dataset have a total depth of 11562 proteins, out of which 11293 are quantified with 
at least two peptides. The number of refined proteins with at least two peptides and no missing 
values in all the treatments was 7398, 8735 and 8551 in A549, MCF-7 and RKO cell lines, 
respectively. Therefore in total, 6496 proteins were quantified in all cell lines with no missing 
values. 
Once again, we used the leave-one-out approach for confirming the validity of the databases 
and their applicability in target/MOA deconvolution. First OPLS-DA models were built for 
compounds in single cell lines and the representative examples are shown in Figure 23. TYMS 
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was among the top three protein for raltitrexed in MCF-7 cells (Figure 23A) and the four top 
proteins mapped to KEGG pyrimidine metabolism (3 proteins, p = 0.0003), which is basically 
the drug MOA. Similarly, tubulins were among the top proteins for vincristine in A549 cells 
(Figure 23B), and several kinase targets were identified as top proteins for dasatinib in different 
cell lines (Figure 23C, F and G). Interestingly, CYP1A1, which is involved in dasatinib 
metabolism (Wang, Christopher et al. 2008), was identified as the top specifically up-regulated 
protein in MCF-7 cells (Figure 23C) and its expression level was extraordinary compared to 
other drugs in this cell line (Figure 23D). The top specifically down-regulated protein in 
response to dasatinib in MCF-7 cells was Poly(ADP-ribose) glycohydrolase (PARG) (Figure 
23C) which was specifically down-regulated in comparison to the other compounds (Figure 
23E). Specific down-regulation of PARG was also noted in the other two cell lines (Figure 
23F-G). While in all the cell lines, the (30) top specifically up-regulated proteins for 
bortezomib show an enrichment of ubiquitin (RPS27A) and other proteins involved in 
ubiquitination (Figure 23H and J), in MCF-7 cells, the top first and fifth most specifically 
down-regulated proteins were dipeptidyl peptidase 2 (DPP7) and dipeptidyl peptidase 3 
(DPP3) respectively, which are known non-proteasomal targets of the proteasome inhibitor 
bortezomib (Arastu-Kapur, Anderl et al. 2011). The specific down-regulation of these two 
proteins in comparison with other compounds is shown in Figure 23I. However, these proteins 
were specific to MCF-7 cells and were not among the top proteins in A549 or RKO cells. These 
results clearly show that inclusion of 9 compounds in a single cell line provides enough 
specificity for drug target and MOA deconvolution in majority of cases. Furthermore, due to 
the special depth of and diversity of cell lines in the dataset, cell-specific targets, low-abundant 
targets (such as kinases), and drug-metabolizing enzymes might also be found.  
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Figure 23. Miniaturized ProTargetMiner captures the targets of compounds in single cell lines with 8 
contrasting compounds. OPLS-DA loadings for A) raltitrexed in MCF-7 cells and B) vincristine in A549 cells. 
The 4 top up-regulated proteins in OPLS-DA loading map to KEGG pathway pyrimidine metabolism (3 proteins, 
p = 0.0003). The targets are highlighted. C) OPLS-DA loading for dasatinib shows multiple kinase targets on top 
rankings in MCF-7 cells; CYP1A1 and PARG as the top most specifically up- and down-regulated proteins, 
respectively. The expression pattern of D) CYP1A1 and E) PARG in the panel of compounds in MCF-7 cells. F-
G) The identification of multiple targets for dasatinib in A549 and RKO cells. H) Bortezomib targets DPP7 and 
DPP3 in MCF-7 cells, but still induces the expression of proteins involved in ubiquitination as shown in the 
pathway (30 top proteins, protein ubiquitination pathway proteins in red). I) The specific down-regulation of DPP7 
and DPP3 in response to bortezomib in comparison with other compounds in MCF-7 cells. J) Up-regulation of 
protein ubiquitination pathway in response to bortezomib in A549 cells and the corresponding pathway analysis 
of 30 top proteins (protein ubiquitination pathway proteins in red). Disconnected proteins not involved in the 
pathway has been omitted. 
4.2.8 Merging deep datasets to obtain a general picture of drug targets and 
MOA 
Next we merged the deep datasets in three cell lines (6496 proteins) to evaluate the performance 
of OPLS-DA in drug target and MOA characterization. Of course, merging would offset the 
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cell-specific targets and MOA, but would provide a general cell-unspecific MOA for 
compounds. When all cell lines were used in the OPLS-DA model, TYMS could be identified 
on first position for raltitrexed and 16th for floxuridine (Figure 24A), showing that inclusion 
of two compounds with similar targets/MOA does not drastically hinder the target 
deconvolution in OPLS-DA. Furthermore, down-regulation of ribosomal proteins in response 
to floxuridine in Figure 24A is a feature of pyrimidine analogues as discussed before (Marin-
Vicente, Lyutvinskiy et al. 2013) and observed in Figure 19. The OPLS-DA loading showed 
the general dasatinib targets and topoisomerase 1 (TOP1) as the target of topotecan among the 
top proteins (Figure 24A). Dasatinib also shows specific up-regulation of CYP51A1 and 
down-regulation of PARG. 
OPLS-DA loading for vincristine in the merged dataset gave microtubule cytoskeleton 
organization (6 proteins, p=0.0105) (Figure 24B) and showed an enrichment of tubulins as 
specifically down-regulated proteins. The down-regulated proteins also mapped to a tight 
pathway representing “poly(A) RNA binding” (13 proteins, p=7.47e-06) and 
“ribonucleoprotein complex biogenesis” (6 proteins, p=0.0444). These pathways are in good 
agreement with previous research showing that vincristine affects RNA synthesis in human 
cells (Wagner and Roizman 1968). The final OPLS-DA model represents nutlin and could 
highlight the cognate target MDM2 at 9th position. While the top specifically up-regulated 
proteins (n=30) mapped to KEGG “p53 signaling pathway” (5 proteins, p < 1.15e-05), the 
specifically down-regulated proteins mapped to multiple pathways in DNA replication 
and repair (GO “DNA repair” (8 proteins, p=0.0001) is highlighted in blue in Figure 
24C). In Figure 24D, we show a dip in the expression of multiple proteins involved in 
DNA repair in response to nutlin compared to other compounds in A549 cells (similar 
results were obtained in other cell lines). Nutlin activates the p53 pathway by antagonizing 
MDM2 (Vassilev, Vu et al. 2004) and is known to slow down DNA repair (Verma, Rigatti 
et al. 2010). Furthermore, DNA repair processes are now known to mediate the p53-
dependent tumor suppression (Janic, Valente et al. 2018). Therefore, the subtle down-
regulation of these proteins can explain why nutlin slows down DNA repair. The subtlety of 
this effect might be the reason why this effect has not been observed before. The 
expression of p53 and MDM2 is shown in Figure 24E. While some other compounds 
also activate p53, the up-regulation is significantly higher in response to nutlin, which 
directly affects p53.  
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Figure 24. Merging deep datasets from three cell lines improves the target ranking in ProTargetMiner.  A) 
OPLS-DA loadings for raltitrexed, floxuridine, dasatinib and topotecan. The known drug targets are highlighted. 
For floxuridine, specific down-regulation of ribosomal proteins is shown. B) OPLS-DA loading for vincristine 
showing the up-regulation of microtubule cytoskeleton organization (6 proteins, p=0.0105) and down-regulation 
of poly(A) RNA binding (13 proteins, p=7.47e-06). The known tubulin targets are shown with red circles. C) 
OPLS-DA loading for nutlin shows the up-regulation of p53 signaling pathway (5 proteins, p=1.15e-05), and 
specific down-regulation of proteins in DNA replication and repair (7 proteins, p = 0.0001). D) The subtle down-
regulation of top DNA repair proteins specifically down-regulated with nutlin in A549 cells. E) The expression of 
p53 and MDM2, the cognate target of nutlin in response to the panel of compounds in A549 cells. Panels D and E 
reused with permission from (Saei, Chernobrovkin et al. 2018). 
4.2.9 ProTargetMiner R Shiny package as a public tool 
The original and deep ProTargetMiner datasets can be easily extended with novel compounds 
in pursuit of their targets and MOA. This possibility was actually shown in the original 
ProTargetMiner dataset when 9 experiments were combined. Therefore, to make the resource 
directly available to the community, a Shiny package was written in R, which provides an 
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interface for integration of user data, matching the proteins with the datasets and OPLS-DA 
modeling in the desired cell line or in the merged dataset (schematics of Shiny package are 
shown in Figure 25). The OPLS-DA loading ranking of all proteins for the submitted 
compound can be extracted. In summary, the user will obtain the proteome signature of a 
compound of interest at LC50 concentration in 48h in any of the above cell lines (or all of them 
for obtaining more power) and feed the gene names and regulations in three replicates to the 
Shiny package. The package output will be an OPLS-DA model contrasting the given 
compound against the other proteome signatures in that cell line, from which a ranking of 
specificity for proteins can be extracted. The state-of-the-art depth of our dataset would 
accommodate the majority of proteome signatures.  
Figure 25. The ProTargetMiner R Shiny package for drug target and MOA deconvolution. In summary, the 
user could obtain the proteome signature of a compound of interest at LC50 concentration in 48h in any of the 
above cell lines (or all of them for obtaining more power) and feed the gene names and regulations in three 
replicates to the Shiny package. The package output will be an OPLS-DA model contrasting the given compound 
against the 9 diverse proteome signatures in that cell line (or 55 in the original set), from which a ranking of 
specificity for proteins can be extracted. Clicking on the interactive PLS-DA plot gives the attributes of the selected 
proteins, e.g. name, number of peptides and sequence coverage, and will show the expression of that protein in the 
relevant dataset compared to the other perturbations. 
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4.2.10 The first human protein correlation database uncovers unexpected 
complexity in protein regulation 
Due to the resource demanding nature of protein synthesis, cells spatiotemporally control 
protein expression (Scott and Pawson 2009). Thus cells reinforce the coordinated expression 
of genes in the same protein complex or pathway (DeRisi, Iyer et al. 1997). Since such co-
expression can indicate functional relationship, “Guilt by association” (Stuart, Segal et al. 
2003) approach has been used for characterization of protein function by analyzing co-
expression (Hughes, Marton et al. 2000). Such databases have so far been based on transcripts 
expression (Stuart, Segal et al. 2003; Zuberi, Franz et al. 2013; van Dam, Craig et al. 2014), 
while it is known that proteomics is more accurate in capturing co-regulation (Wang, Ma et al. 
2017). To the best of our knowledge, no large-scale proteomics-based protein correlation 
database exists. 
As the 55 compounds used in this study perturbed the majority of the proteome, 
ProTargetMiner presented the opportunity to build the first human protein pairwise correlation 
database solely based on proteomics data (Figure 26).  
Moreover, such a database can provide information on the complexity of protein regulation. 
Furthermore, the pair-wise anti-correlation of protein abundances is usually neglected in such 
databases. This is while there is a lower chance for negative correlations (than positive 
correlations) to result from technically-induced artifacts (Lee, Hsu et al. 2004). Such protein 
anti-correlation can potentially represent opposing biological processes, where they are wired 
for example in active transcriptional repression, transcriptional activation or even canceling of 
such events (Struhl 1999). Protein pairwise anti-correlation was therefore included in the 
current study, and physical interpretation of anti-correlation is an open opportunity.  
After refining, removal of the batch effects and data filtering, a 4212 x 4212 correlation matrix 
was made for the original ProTargetMiner dataset (Figure 27). At least 11 clusters could be 
recognized in the matrix. For instance, the 129 proteins present in cluster 8 mapped to 
ribosomal proteins (n=72) and ribosome biogenesis (n=10). From the 17,740,944 correlation 
pairs in the matrix, a high-confidence set (FDR<0.001) of 103,928 positively and 51,137 
negatively correlating protein pairs were chosen. The lower frequency of negative in 
comparison with positive correlations was expected and was consistent with a previous study 
(Lee, Hsu et al. 2004).  
Figure 26. Analyzing pair-wise protein correlation in 
ProTargetMiner. The proteome perturbation by 55 anticancer 
compounds will uncover protein co-regulation and anti-
correlation networks and facilitate the functional annotation of 
uncharacterized proteins. Figure adapted with permission from 
(Saei, Chernobrovkin et al. 2018). 
Co-regulation
Correlations
Anti-correlation Co-regulation
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4.2.11 The database pulls out dense regions of protein interaction networks 
The 10 top correlating pairs (r>0.98) mostly mapped to dense interaction networks and protein 
superfamilies, e.g., protein complexes, such as MCM, condensin, ribosome, chaperonin-
containing T and mitochondrial respiratory chain as well as tubulins. In Figure 28 we mapped 
the top 2500 co-regulated pairs, which clearly form functionally coherent groups of genes.  
For making the database available for network visualization and pathway analysis, we mapped 
the data to StringDB entities and created a set of external payload data. These payload data can 
thus be uploaded to StringDB as nodes and edges. Known StringDB interactions and 
ProTargetMiner correlations can be visualized simultaneously using this approach.  
Figure 27. Analyzing pairwise protein 
correlations in ProTargetMiner 
across 55 perturbations. A correlation 
matrix of 4,212 proteins. Vertical axis: 
broken-down to 11 clusters. Note the 
high abundance of anti-correlations 
(blue color) and the existence of clear 
cut corners in the matrix. Figure reused 
with permission from (Saei, 
Chernobrovkin et al. 2018). 
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Figure 28. Top co-regulating proteins in ProTargetMiner. The top 2500 correlating pairs map to dense 
protein interaction networks, indirectly validating the approach. Figure reused with permission from (Saei, 
Chernobrovkin et al. 2018). 
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4.2.12 Protein anti-correlation, true or false? 
TIGAR (TP53-inducible glycolysis and apoptosis regulator) was one of the top and enriched 
anti-correlating proteins. Therefore, we set out to examine its expression pattern against its 
most anti-correlating pair NCAPG (condensin complex subunit 3) (r=-0.84) (Figure 29A). A 
pathway analysis was performed for TIGAR and NCAPG, along with 5 most correlating 
proteins for each (Figure 29B). While 3 proteins from the TIGAR group gave p53 signaling 
pathway (p < 0.002), 5 proteins from the NCAPG group mapped to condensin complex and 6 
to cell division (p < 0.001). This result is in good agreement with the observation that p53 
inhibits entry into mitosis upon a blockage of DNA synthesis. Furthermore, TIGAR is 
known to protect from accumulation of genomic damage in a p53-dependent manner 
(Bensaad, Tsuruta et al. 2006). Interestingly, one of the proteins strongly co-regulating 
with TIGAR (r=0.89) was CMBL, but this protein was not annotated in the p53 
signaling pathway in StringDB. However, CMBL has been identified as a p53-inducible 
protein in a microarray screen (Jiang, Kon et al. 2015). These findings confirm the 
predictive power of the database and serve as an in silico proof-of-concept.  
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Figure 29. Comprehensive analysis of protein pairwise correlation considering up- and down-regulation. 
A) The anti-correlation of TIGAR with NCAPG. B) All the top proteins which are co-regulating with TIGAR anti-
correlate with those co-regulating with NCAPG. The blue links reflects information available in StringDB and the
red links reflects newly established links in ProTargetMiner. C) The anti-correlation of up or down-regulated
TIGAR vs. NCAPG (plots 1 and 2) and up- or down-regulated NCAPG vs. TIGAR (plots 3 and 4). D) Any protein
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pairs give two sets of correlations separately considering their up and down-regulation status. E) Map of pairwise 
correlations between proteins A and B, separately for up- and down-regulation states of protein A. The red circles 
reflect the positions (center) and volumes of 5 fitted 2D Gaussian distributions. The green boxes reflect protein 
pairs that only have strong correlations in one direction. F) 2D Gaussian fitting performs best with 5 components. 
G) Similar analysis as in panel F using scrambled protein abundances. Caption adapted from Paper II (Saei, 
Chernobrovkin et al. 2018). Figure adapted with permission from (Saei, Chernobrovkin et al. 2018).
4.2.13 Adding complexity to protein regulation 
However, this was not the whole story. While the overall TIGAR vs. NCAPG anti-
correlation coefficient was significant (r=-0.84) (Figure 29A), the slope was -0.75 and not 
-1, signifying an underlying complexity. When TIGAR’s regulation was above-average, it 
anti-correlated more strongly with NCAPG (r=-0.75, plot 1 on Figure 29C) than when it 
had a regulation below average (r=-0.52, plot 2). Also, in the first scenario, the slope was 
close to -0.97, as if in perfect association; but with TIGAR down-regulated, the slope 
reduced to -0.56. On the contrary, when NCAPG had a regulation above average, the anti-
correlation with TIGAR was weak (r=-0.23, plot 3), whereas when down-regulated, it had 
a strong anti-correlation with TIGAR (r=-0.80, slope -1.01, plot 4). 
These findings revealed an expected but neglected bimodality in anti-correlation. This 
prompted us to calculate two correlation coefficients for every protein pair (Figure 29D). 
Therefore, we calculated two separate correlations for above and below the median abundance 
of protein A (in the pair A vs. B). The heatmap of these correlations on a 2D plot with a cutoff 
of |r|>0.54 (Figure 29E) unexpectedly revealed five dense areas (circles 1-5 in Figure 29E), 
which were confirmed by fitting symmetric 2D Gaussian distributions (Figure 29F). The 
positions of these Gaussians are shown as the centers of red circles in Figure 29E, and their 
volumes (frequency of pairs) correspond to circle areas. Scrambled protein abundances gave a 
single central spot (Figure 29G) rather than an elliptic symmetry, confirming that spots 2-4 are 
not artifacts.  
Entity 1 or “highly co-regulated” (average r=0.52) contains 12% of the total number of (anti-) 
correlating protein pairs, and the 300 top protein pairs (r ≥ 0.90) map to ribosome, MCM, 
condensin, chaperonin-containing T, NADH dehydrogenases and pyruvate dehydrogenase 
complexes as well as tubulin superfamily, some integrins and spectrins. The center of entity 1 
is above the diagonal, indicating a higher co-regulation when the protein pairs are down-
regulated that up-regulated. This asymmetry can be explained by the fact that down-regulation 
can reach zero, whereas up-regulation cannot reach infinity. Another biological explanation is 
that there is usually no natural stopper for up-regulation, while degradation is under a higher 
level of control, and slows down or stops with only strongly bound stoichiometric complexes 
remaining in the system.  
In general, positive and negative components account for 55% and 33% of total protein pairs, 
respectively. The protein pairs in entity 2 or “co-down-regulated” show better co-regulation 
when down-regulated (average r=0.5 vs. average r=0.3). Entity 2 harbors 23% of correlating 
pairs. Entity 3 or “co-up-regulated” proteins is composed of proteins correlating more when 
49 
up-regulated (average r=0.5) than when down-regulated (average r=0.28). Entity 3 possesses 
32% of correlating pairs. 
The protein pairs in entity 4 or “anti-correlating” exhibit a higher anti-correlation when protein 
A regulation is below average (average r=-0.29 vs. r=-0.46), while entity 5 or “negatively 
regulated” displays higher anti-correlation when protein A is up-regulated (average r=-0.45 vs. 
r=-0.29). Entities 4 and 5 have a comparable frequency of protein pairs (16% and 17%, 
respectively). These findings are discussed in more detail in Paper II (Saei, Chernobrovkin et 
al. 2018).  
In Figure 29E, a number of protein pairs show strong anti-correlation in one and around zero 
correlation in the other direction. For example, in region 1’, out of the 50 top pairs, 28 proteins 
(both “A” and “B” type) map to negative regulation of cellular processes (p < 0.03). In region 
2’, 11 “A” proteins from 50 pairs give “cell cycle” (p < 0.005), while 5 “B” proteins gave 
“nucleotide excision repair” (p < 2.1E-06) and 7 “B” proteins – mapped to “cellular response 
to DNA damage stimulus” (p < 0.022), exposing the former and the two latter pathways as 
potentially opposing ones (Hustedt and Durocher 2017). The top 50 pairs in region 4’ give 
“ribosome” (16 proteins, p < 2.3E-15) and “ribosome biogenesis” pathways (14 proteins, p < 
1.0E-12). 
4.2.14 Anti-correlation provides further information on protein regulation 
The anti-correlation data can potentially furnish further information on protein regulation. For 
instance, TRIM28 when regulated above average, strongly (r<-0.61) anti-correlates with 34 
proteins mapping to focal adhesion (7 proteins, p < 8.1E-06). Interestingly, a recent study has 
directly linked TRIM28 to cell adhesion (Klimczak, Czerwińska et al. 2017). Furthermore, the 
other enriched pathway was that of ErbB signaling (4 proteins, p < 0.001). TRIM28 is known 
to directly interact with ErbB4 and inhibit its transcriptional activity (Gilmore-Hebert, 
Ramabhadran et al. 2010). 
4.2.15 Untouchable proteome reflects essential cell functions 
We further analyzed to data to investigate if there are proteins with steady expression in 
response to the compound panel, designating the untouchable or core proteome (Figure 30). 
Figure 30. The core and variable proteomes. The 
untouchable or core proteome is defined as a set of proteins 
with steady expression across the treatments. Figure reused 
with permission from (Saei, Chernobrovkin et al. 2018). 
Core or
untouchable 
proteome
Variable
proteome
 50 
To identify core proteins, the standard deviation of expression for all the proteins was 
calculated in the original ProTargetMiner dataset. The 100 most stably expressed proteins 
mapped to proteasome (9 proteins, p < 2E-10), spliceosome (8 proteins, p < 3E-05), and mRNA 
surveillance pathway (6 proteins, p < 0.001). These pathways might represent the core cellular 
functionalities. The fact that proteins from the proteasome and spliceosome were among the 
enriched pathways is remarkable, as we had a number of proteasome inhibitors and proteins 
targeting components of the spliceosome in the library. This shows the great level of control 
and buffering of expression in these complexes and networks. 
 
4.2.16 Untouchable proteome unravels house-keeping proteins 
In comparative proteomics and other molecular biology techniques, and in particular Western 
blots, specific proteins are used as internal references, assuming that they have a steady 
expression. Examples of such housekeeping proteins (HKPs) include GAPDH, β-tubulin and 
β-actin. Such proteins have been selected because of their high mRNA expression levels and 
consistent expression in different cells and tissues. However, stable expression under treatment 
conditions has not been studied for most of these proteins. Indeed, in practice, a number of 
these HKPs show inconsistent expression levels under different treatments (Vigelsø, Dybboe 
et al. 2014; Janes 2015; Lee, Jo et al. 2016). For example, GAPDH, one of the most extensively 
used HKPs showed variable expression in our compound panel especially for bortezomib 
(Figure 31A). These inconsistencies can lead to inaccurate estimation of protein abundance, 
as reported before (Dittmer and Dittmer 2006; Li and Shen 2013; Collins, An et al. 2015; 
Gough 2015). Therefore, characterization of ideal HKPs is an active area of research 
(Eisenberg and Levanon 2013). 
ProTargetMiner presented an opportunity to identify reliable HKPs. We used standard 
deviation across all the treatments for rank ordering of most stably expressed proteins (Figure 
31B). The exemplary expression profiles of two proteins with most steady and variable 
expression are depicted in Figure 31C. More analysis will be done to assess the reliability of 
potential HKPs (with regards to abundance, number of peptides, presence in various cell lines 
and tissues, availability of reliable antibodies, etc.) and presenting a shortlist of top candidates.  
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Figure 31. In search for more reliable housekeeping proteins. A) GAPDH expression across the treatments. B) 
Distribution of standard deviations of 6,032 proteins across the compounds panel. C) Typical proteins exhibiting 
highest and lowest stability across the compound panel. Data are represented as mean±SD. Figure adapted with 
permission from (Saei, Chernobrovkin et al. 2018). 
Conclusions 
In summary, ProTargetMiner can be considered as a resource of proteome signatures for a 
panel of FDA-approved compounds. ProTargetMiner R Shiny package serves as a platform for 
deconvolution of targets, MOA, resistance factors and other specific effects for novel 
compounds. The specificity concept enabled by OPLS-DA modeling can be a viable approach 
in characterization of subtle but biologically meaningful phenomena in target deconvolution in 
proteomics and other big data, as well as nuances of differences in protein expression 
potentially involved in tissue diversification (Silva and Vogel 2016).  Furthermore, the analysis 
of ProTargetMiner data provided insight on the complexity of protein regulation. The 
correlation database can be used for characterization of proteins with unknown functions. 
Finally, the most stably expressed proteins in the ProTargetMiner data can be used as HKPs in 
molecular biology experiments. 
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4.3 PAPER III. COMPREHENSIVE CHEMICAL PROTEOMICS PREDICTS 
DRUG TARGETS: AURANOFIN AS EXAMPLE 
In Paper III, we used a series of chemical proteomics tools –namely TPP, FITExP and 
multiplexed redox proteomics for prediction of targets and characterization of mechanism 
space for auranofin. Auranofin was approved by FDA in 1985 as an antirheumatic agent, but 
recent studies have shown its potent antitumor activity (Rios Perez, Roife et al. 2016) and is 
therefore being evaluated in clinical trials against ovarian cancer (NCT03456700), chronic 
lymphocytic leukemia (NCT03456700) and lung cancer (NCT03456700) (Roder and Thomson 
2015). Auranofin is known to bind to the selenocysteine- (Sec-) active site in thioredoxin 
reductase 1 (TXNRD1). However, surprisingly several different mechanisms have been 
proposed for auranofin and controversies exist regarding its cellular targets and potentially 
important off-targets remain unexplored. Full characterization of auranofin mechanistic space 
can help adjust and justify its repurposing context. 
 
4.3.1 Unbiased prediction of auranofin targets using a combination of 
chemical proteomics tools  
Since each chemical proteomics methods yields both false positives and false negatives, 
multiple tools must be explored and combined to get a reliable list of target proteins, each 
supported by one or more technique. Therefore, a series of experiments were performed for 
auranofin: Two TR-TPP experiments in cells (2 and 3 µM in HCT116 cells for 2h), a TR-TPP 
experiment in lysate (500 nM in HCT116 cells), a FITExP experiment (HCT116, RKO and 
A375 cell lines treated for 48h with LC50 concentrations; methotrexate, OSW-1 and paclitaxel 
were used as contrasting compounds) and a redox experiment (3 µM in HCT116 cells for 2h). 
An overview of the results in shown in Figure 32A-C. 
For de novo and unbiased identification and validation of auranofin targets, we ranked the 
proteins in each chemical proteomics experiment. In TR-TPP experiment in cells (3 µM 
auranofin) and lysate, the proteins were ranked based on the ∆Tm between auranofin and 
control treatments, and in FITExP, absolute magnitude of consistent regulation in three cell 
lines was used for ranking of proteins. In redox proteomics, the proteins were ranked based on 
the difference in oxidation level and p values of auranofin vs. vehicle-treated samples. The 
rankings from all mentioned experiments were combined to shortlist candidate drug targets 
(Figure 32D). Proteins with the lowest cumulative ranking are therefore the best drug target 
candidates.  
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Figure 32. Unbiased prediction of auranofin targets by chemical proteomics tools. A) Overview of 
FITExP data for auranofin and three contrasting compounds from three cell lines. B) Redox proteomics 
revealed an increase in the oxidation level of many peptides and a decrease in some upon treatment with 
auranofin. C) TPP data for 1887 proteins with ≤1 °C difference between the two replicates in 3 µM auranofin 
treatment of HCT116 cells shows stabilization of several proteins. Some of these proteins, including 
GABPB1, RRM1 and SRXN1 are known to be regulated by thioredoxin system. D) The cumulative ranking of 
target candidates in four different types of analysis (FITExP, TR-TPP in cells and lysate, as well as redox 
proteomics). Proteins with the lowest overall rankings are top candidate targets (TXNRD1 is the cognate 
target). E-G) Changes in the expression, oxidation of top constituent peptides and stability of three top target 
proteins in cells (none of these proteins changed their stability in cell lysate). H) Top 15 proteins were 
analyzed with Functional Annotation Clustering tool in DAVID. Top pathways enriched with minimal 
redundancy (fold enrichment >5 and p < 0.01), representing the dominant mechanisms for auranofin, are 
shown. 
The expression vs. control in three cell lines, the oxidation level of the most oxidized 
peptide as well as the melting of three top proteins in cells in response to auranofin are 
shown in Figure 32E-G. Using this unbiased approach, TXNRD1 was on found on the 
3rd position. Since  TXNRD1 is the cognate target for auranofin, the predictive power of 
chemical proteomics is  confirmed. This was an impressive result, as the lowest ranking 
for auranofin in any method was in FITExP, where TXNRD1 was ranked 15th. TXNRD1 
had a cell line dependent up-regulation. CDYENVPTTVFTPLEYGACGLSEEK was 
the top oxidized peptide for TXNRD1 with a ratio of 2.53 (p = 0.051) 
auranofin:DMSO. TXNRD1 was slightly but reproducibly stabilized in cells (1.14 °C 
with 3 µM and 1.02 °C with 2 µM auranofin) and not in the lysate, perhaps indicating a 
chemical transformation prior to attachment to TXNRD1. Indeed, it is known that 
auranofin  binds to  TXNRD1  selenocysteine and  subsequently  gold  is  transferred  to the  
−0.5
−1
−1.5
M
e
th
o
tr
e
x
a
te
O
S
W
-1
P
a
c
li
ta
x
e
l
A
u
ra
n
o
ﬁ
n
P
a
c
li
ta
x
e
l
A
u
ra
n
o
ﬁ
n
M
e
th
o
tr
e
x
a
te
O
S
W
-1
O
S
W
-1
M
e
th
o
tr
e
x
a
te
P
a
c
li
ta
x
e
l
A
u
ra
n
o
ﬁ
n
0
0.5
1
HCT116
A375
RKO
-4
Tm Aura - Tm DMSO (rep 1)
)
T
m
 A
u
ra
 -
 T
m
 D
M
S
O
 (
re
p
 2 GABPB1
OGFR
UBA1
CCS
MAP2K7
-2
2
4
6
-4 -2 2 4 6 8
GLOD4
TXNRD1
SRXN1
r  =0.71
4
3
2
1
0
DMSO
Auranoﬁn
Redox
ProteomicsFITExP
Thermal proteome proﬁling
BA
C
0.0
0.5
1.0
40 50 60
TXNRD1
0.0
0.5
1.0
40 50 60
Auranoﬁn
DMSO
NFKB2
F
o
ld
 c
h
a
n
g
e
 v
s
. 
c
o
n
tr
o
l
0.0
0.5
1.0
40 50 60
CHORDC1
F
ra
c
ti
o
n
 
n
o
n
-d
e
n
a
tu
re
d
F
ra
c
ti
o
n
 
n
o
n
-d
e
n
a
tu
re
d
F
ra
c
ti
o
n
 
n
o
n
-d
e
n
a
tu
re
d
0
0.5
1
1.5
2
2.5
HCT116 A375 RKO
NFKB2 CHORDC1
TXNRD1
0
0.1
0.2
0.3
0.4
N
F
K
B
2
C
H
O
R
D
C
1
T
X
N
R
D
1
O
x
id
a
ti
o
n
 l
e
v
e
l
O
x
id
a
ti
o
n
 r
a
ti
o
Auranoﬁn
DMSO
Cell lines
E
Temperature (
 o
C)
F
G
p=0.05
p=0.02
p<0.00
0 5 10 15 20 25
Oxidoreductase
Nucleotide phosphate-binding region:FAD
NADP
mRNA processing
Flavoprotein
mRNA splicing, via spliceosome
Response to reactive oxygen species
Fold Enrichment
5
- log
10
(p)
2.5
H
Major pathways by Functional Annotation Clustering
 2
L
o
g
2
(e
x
p
re
s
s
io
n
 v
s
. 
c
o
n
tr
o
l)
0
100
200
300
400
500
600
700
C
u
m
u
la
ti
v
e
 r
a
n
k
in
g
 o
f 
2
0
0
 t
o
p
 p
ro
te
in
s
D
ELAVL1
NFKB2
CHORDC1
TXNRD1KEAP1
RRM1
Proteins
54 
redox active cysteine couples inside the protein (Angelucci, Sayed et al. 2009). The 
slight change in TXNRD1 stability though might be linked to auranofin binding to the 
penultimate amino acid, which may not induce a significant stability change in the 71 kDa 
macromolecule.  
The other two top shortlisted proteins were not known as auranofin targets. The top 
protein was Nuclear factor NF-kappa-B p100 subunit (NF-kB2), the inhibition of which is 
responsible for the anti-inflammatory effects of auranofin (Jeon, Jeong et al. 2000; Youn, 
Lee et al. 2006). Although the direct binding of auranofin to NF-kB2 has not been 
reported in literature, the appearance of this protein in the list cannot be by chance. 
Therefore, we will examine if NF-kB2 is a direct target of auranofin by follow-up 
experiments. CHORDC1 or cysteine and histidine-rich domain-containing protein ranked 
second before TXNRD1 and is known to be involved in HSP90 chaperone complex and 
stress response (Ferretti, Palumbo et al. 2010). CHORDC1 is rich in cysteines, but it is 
an unknown protein in the context of thiol-reactive metal compounds. 
4.3.2 Pathway analysis reveals the major auranofin mechanism 
To lower the risk of false negatives stemming from taking the interception of top results 
from different analyses, we selected fifteen top proteins from each of the four methods and 
subjected the combined list to pathway analysis by Functional Annotation Clustering tool 
in DAVID. This new tool helps reduce the number of redundant biological pathways by 
grouping similar annotations together (Huang, Sherman et al. 2008). The top enriched 
pathways by p value were “oxidoreductase”, “nucleotide phosphate binding region (NAD)” 
and “NADP”, in line with the MOA of auranofin (Figure 32H). 
We looked further in the expression data to decipher which proteins are involved 
in oxidoreductase pathways. The expression data for auranofin were clustered (Figure 
33A). The clustering grouped the data first based on the three cell lines. Interestingly, 
the cluster 6 consisted of 15 proteins up-regulated in all three cell lines, demonstrating 
that FITExP is an effective approach for discovery of proteins with consistent behavior in 
a panel of cell lines (Chernobrovkin, Marin-Vicente et al. 2015). These 15 proteins 
formed a tight group, irrespective of the chosen number of clusters (n=6-10) and 
mapped to “glutathione (GSH) metabolic process” (4 proteins, p < 0.0004) and “response 
to oxidative stress” (4 proteins, p < 0.0005). Although auranofin induced different proteome 
signatures in different cell lines, the up-regulation of GSH metabolism related proteins was 
noted in all cell lines. The induction of enzymes playing a role in GSH metabolism is 
consistent with the backup role of GSH in the absence of TXNRD1 activity (Du, Zhang et 
al. 2012). Furthermore, interestingly, most of the proteins in cluster 6 are Nrf2 target 
proteins (highlighted in red in Figure 33A). TXNRD1 inhibition is known to activate 
Nrf2 (Cebula, Schmidt et al. 2015), which in turn induces the expression of genes involved 
in the response to oxidative stress such as GCLM and GCLC (GSH synthesis enzymes) 
(Malhotra,  Portales-Casamar  et al.  2010). The  biological  pathways  enriched  for  30  top 
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up-regulated proteins from FITExP are shown in Figure 33B. 
Figure 33. The over-representation of Nrf-2 targets and oxidoreductase pathways in response to auranofin. 
A) The clustering of auranofin expression in three cell line gave a tight cluster (6), consisting of 15 proteins up-
regulated in all cell lines. The pathways enriched for top 30 proteins in FITExP (B) and proteins changing stability
in TPP (C).
Next we analyzed the stability data in cells for finding proteins responding to auranofin 
treatment by a change in stability. We subjected the proteins (with at least three peptides) with 
≥1.5 °C ΔTm between auranofin and DMSO treatments in the TR-TPP with 3 µM auranofin 
to pathway analysis. These proteins mapped to “antioxidant activity” (Figure 33C). Therefore, 
both FITExP and TPP methods showed the perturbation of oxidoreductase pathways in cells 
treated with auranofin indicating that perturbation of oxidoreductases is the main MOA for 
auranofin. 
4.3.3 Redox proteomics links cysteine oxidation and protein stability 
Another hypothesis that we pursued in this study was if protein oxidation in the peptide level 
(measured with redox proteomics) can be linked to change in stability of the respective proteins 
(measured in TPP). Cellular thioredoxin system is tasked with reduction of specific substrate 
proteins (Arnér and Holmgren 2000), which in turn reduce other cellular proteins. Auranofin-
mediated inhibition of this system could consequently lead to stabilization of these substrates 
and perhaps down-stream proteins. Therefore, the redox proteomics experiment was performed 
under similar conditions to TPP, treating HCT116 cells with 3 µM of auranofin for 2h. The 
higher oxidation of peptides in auranofin vs. DMSO treatment was obvious in the asymmetric 
volcano plot (Figure 34A) in favor of more oxidation. We could link the oxidation/reduction 
of 11 to increased or decreased thermal stability in TPP (shown in red in Figure 34A). 
Interestingly, the active sites of SRXN1 (Cys99) –which is the only cysteine residue in this 
protein, (Sunico, Sultan et al. 2016) and PRDX5 (Cys100) (Seo, Kang et al. 2000; Hall, 
Parsonage et al. 2010) were among these sites (Figure 34B). The melting curves of SRXN1 
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and PRDX5 along with two other representative proteins with simultaneous change in 
oxidation and stability is shown in Figure 34C. Therefore, a combination of TPP and redox 
proteomics can be used for discovery of potential redox regulatory switches in proteins, and 
extend the applications of both techniques. 
Figure 34. Peptide oxidation state can be potentially linked to protein stability. A) The oxidation rate of 
cellular peptides after treatment with 3 µM auranofin for 2h. The highlighted peptides with significant change in 
oxidation state are those for which the respective proteins change stability in TPP. B) Significant oxidation and 
reduction of SRXN1 and PRDX5 active sites in redox proteomics. C) Change in the stability of SRXN1 and 
PRDX5 in TPP. PHF5A and RRM1 as other representative proteins which had significantly oxidized peptides and 
higher stability in response to auranofin. 
Conclusions 
Taken together, we showcased the efficiency of chemical proteomics for prediction of the target 
and MOA of auranofin. As expected, different techniques have various strengths and 
weaknesses, and must be used in parallel for obtaining the most reliable targets. Another 
important finding of this study was that redox proteomics can be combined with TPP to 
discover downstream redox events with effect on protein stability, and potentially map them to 
redox-active or generally active sites. 
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4.4 PAPER IV. THE DEUBIQUITINASE INHIBITOR B-AP15 INDUCES STRONG 
PROTEOTOXIC STRESS AND MITOCHONDRIAL DAMAGE 
In Paper IV, we applied quantitative multiplexed proteomics to delineate the phenotypic 
response of colon cancer cells to b-AP15 in comparison with another proteasome inhibitor 
bortezomib. b-AP15 belongs to the bis-benzylidine piperidone compound family, which have 
been shown to effectively kill apoptosis-resistant cells, as shown in several tumor models. b-
AP15 is known to inhibit deubiquitinases USP14 and UCHL5. Although the mRNA and 
protein expression profiles for b-AP15 and bortezomib were quite similar, b-AP15 induced a 
more significant expression of chaperones. Furthermore, polyubiqutinated proteins 
accumulated to a higher degree in response to b-AP15 than bortezomib, which were shown to 
co-localize with organelle membranes such as mitochondria. Such a phenomenon reduced the 
mitochondrial oxidative phosphorylation. This reduction was exacerbated by severe 
proteotoxic stress, down-regulation of VCP/p97 and inhibition of endoplasmic reticulum 
translocation. The overall results indicated that the co-localization of misfolded proteins with 
mitochondrial membrane might underlie the atypical cell death mode. The effect of b-AP15 on 
mitochondrial cluster of proteins was also obvious in Paper II. Therefore, compounds 
targeting mitochondria might be promising for eradication of apoptosis resistant tumors. 
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4.5 PAPER V. SYSTEM-WIDE IDENTIFICATION OF ENZYME SUBSTRATES 
BY THERMAL ANALYSIS (SIESTA) 
Many proteins modify their specific substrates by post-translation modification. In addition to 
expression level, protein regulation and numerous cellular processes are modulated with PTMs 
(Mann and Jensen 2003). PTMs are capable of changing several protein attributes such as 
function, stability, hemostasis and localization (Houde, Peng et al. 2010), and can ultimately 
dictate cellular diversification as an independent regulator along with protein expression. 
Therefore, the identification and characterization of PTMs and their biological consequences 
has emerged as a growing and lively research area (Weinert, Narita et al. 2018).  
A central paradigm in PTM research is characterizing enzyme-substrate associations. Such 
knowledge is crucial for the fundamental understanding of cell biology in general and disease 
mechanisms in particular. In addition, modified substrates provide an output and are an integral 
component of many high-throughput screening assays in drug discovery (Von Ahsen and 
Bömer 2005). The development of therapeutics for several conditions such as Parkinson's 
disease (Steger, Tonelli et al. 2016) and cancer (Byrd and Blagg 2018) is in certain cases 
hampered by the lack of knowledge on the physiological substrates of enzymes for developing 
such screens.  
In spite of the importance of enzyme-substrate associations, generic proteome-wide methods 
for characterizing the molecular entities partaking in these reactions are not available. Specific 
substrates for enzymes can be experimentally identified by several techniques such as creating 
substrate-trapping mutants (Flint, Tiganis et al. 1997), peptide immunoprecipitation 
(Matsuoka, Ballif et al. 2007), affinity purification-mass spectrometry (Low, Peng et al. 2014), 
employing peptide (Köhn, Gutierrez‐Rodriguez et al. 2007) or protein arrays (Feilner, 
Hultschig et al. 2005), using genetic and pharmacologic perturbations (Yen and Elledge 2008) 
and client proteins tagging by substrate analogues using engineered enzymes (Ubersax, 
Woodbury et al. 2003). However these methods are developed for a certain enzyme (class), 
take long to optimize and are not straightforward. Furthermore, engineered enzymes might 
change the biology of the system under study, and are prone to false positive discoveries. 
Therefore, developing an unbiased system-wide tool for discovery of specific enzyme 
substrates can be a significant advance.  
It was previously known that protein stability can shift upon interaction with metabolites, 
proteins and nucleic acids (Park and Marqusee 2005; Niesen, Berglund et al. 2007; Molina, 
Jafari et al. 2013; Savitski, Reinhard et al. 2014). Proteome-wide techniques such as TPP can 
be used to measure protein stability changes arising from such interactions (Savitski, Reinhard 
et al. 2014). PTMs have also been postulated to alter thermal stability of substrate proteins 
(Becher, Andres-Pons et al. 2018; Dai, Zhao et al. 2018; Drake, Hou et al. 2018). Therefore, 
one could theoretically add a recombinant enzyme and its co-factor to the cell lysate and 
monitor the thermal stability of proteins in a proteome-wide manner, to reveal enzyme substrate 
proteins with shift in stability (Savitski, Reinhard et al. 2014). A PTM-induced shift in stability 
can hypothetically arise from conformational transitions, promoting or disruption of protein-
protein interactions, etc. 
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However, the enzyme-protein and co-factor-protein interactions can also happen and mask the 
substrate proteins. In our method called System-wide Identification of Enzyme Substrates by 
Thermal Analysis (SIESTA), we solved this problem by tracking specific thermal stability 
changes of substrate proteins (Saei, Astorga Wells et al. 2018). Meaning that stability changes 
in the candidate substrate proteins induced by a combination of enzyme and co-factor are 
contrasted to stability changes induced by enzyme or co-factor alone in OPLS-DA. The method 
workflow is shown in Figure 35.  
Figure 35. SIESTA workflow. Cell lysate is prepared in a non-denaturing buffer by several freeze-thaw cycles 
to preserve the native conformation of proteins. Cell lysate aliquots are then treated with vehicle, co-factor, enzyme 
or both. After the treatment period, each condition is split into 10 microtubes, and each microtube is heated to a 
temperature point in the 37-67 °C range. After ultracentrifugation to remove unfolded proteins, identical volumes 
of supernatants are taken for digestion with trypsin. Thereafter, the samples are labeled with 10-plex TMT, pooled, 
cleaned by SepPak and fractionated by reversed-phase chromatography. The fractions are then analyzed by LC-
MS/MS to quantify the proteins. Finally, after sigmoid curve fitting, melting temperature Tm is determined for 
each protein. The candidate substrate proteins for an enzyme are thus those that show a larger stability change 
upon addition of enzyme-co-factor combination and should be validated by orthogonal methods. Figure reused 
with permission from (Saei, Astorga Wells et al. 2018). 
4.5.1 SIESTA identifies known and putative TXNRD1 substrates 
We used the thioredoxin reductase 1 (TXNRD1) as a proof of principle system. Using NADPH 
as a co-factor, TXNRD1 reduces the disulfide bonds in a limited number of specific substrate 
proteins (Arnér and Holmgren 2000). Such a reduction should destabilize the structure of 
substrate proteins and may lead to negative ∆Tm. We therefore treated the HCT116 cell lysate 
with vehicle, 1 mM NADPH, 1 µM TXNRD1, or both. Samples were prepared according to 
the workflow in Figure 35. 
As expected, NADPH treatment stabilized several proteins known to interact with this co-factor 
(Figure 36A-B). TXNRD1+NADPH treatment specifically destabilized known substrate 
proteins (Figure 36C). Furthermore, as observed in Figure 36C, an expected asymmetry in 
Tm shifts was noted in favor of destabilization, in line with TXNRD1 function. In an OPLS-
DA model, TXNRD1+NADPH treatment was contrasted with the three other treatments to 
reveal the specifically destabilized proteins (Figure 36D). The melting curves for a number of 
known and putative TXNRD1 substrates are shown in Figure 36E. In total, 28 candidate 
substrates were found and mapped to the following INTERPRO Protein Domains and Features 
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pathways: “thioredoxin-like fold” (8 proteins) and “peroxiredoxin, C-terminal” (4 proteins) (p 
< 0.001). These pathways are in line with the key physiological functions of TXNRD1 (Arnér 
and Holmgren 2000).  
The protein showing the largest shift in stability was GPX1 (Figure 36C-E), which
is a selenoprotein usually supposed to be GSH-dependent (Brigelius-Flohé and Maiorino 
2013). However, TXNRD1 can directly reduce some GPX isoenzymes (Björnstedt, Xue et 
al. 1994). Several identified candidates such as peroxiredoxins (PRDXs) (Chae, Kim et al. 
1999), TXNL1 (or TRP32) (Jiménez, Pelto-Huikko et al. 2006), NXN (Funato, Michiue et 
al. 2006), as well as GSTO1 and GSTO2 (Board, Coggan et al. 2000) are well-known 
substrates of TXNRD1 or TXNRD1-dependent enzymes. The other proteins identified in 
this screen are thus putative substrates of TXNRD1. 
Figure 36. SIESTA experiment on the proof-of-principle TXNRD1 system revealed a number of known and 
putative substrates. A) A linear regression was performed on SIESTA results for control and NADPH (95%-
prediction interval as a cutoff). The outlier proteins are known (purple circles) or putative NADPH binders. B)  
Thermal stability shifts for known NADPH binding proteins IDH1 and NMRAL1. C) A Tm differences scatterplot 
shows the shifts occurring only after adding a combination of TXNRD1 and NADPH; these shifts arising from 
enzymatic modifications (known and putative substrates as red circles). D) An OPLS-DA model contrasting the 
“TXNRD1+NADPH” Tm vs. all other treatments reveals potential substrates (red circles) located on the negative 
extremity of x axis (black square). E) Exemplary melting curves of known (GPX1 and PRDX6) and putative 
substrates (COPS5, GULP1, ETHE1 and RNASET2) for TXNRD1. Figure reused with permission from (Saei, 
Astorga Wells et al. 2018). 
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4.5.2 SIESTA identifies many novel putative substrates for PARP10 
Poly-(ADP-ribose) polymerase-10 (PARP10) was the second system where we applied 
SIESTA. PARP10 belongs to the PARP family of proteins and is only capable of performing 
mono-ADP ribosylation (Kleine, Poreba et al. 2008). This reaction takes place in the presence 
of NAD as a co-factor. ADP-ribosylation is involved in signaling, DNA repair, regulation of 
gene expression and cell death (Gupte, Liu et al. 2017). The glycosidic and thus the labile 
nature of this modification makes it difficult to detect this PTM by MS/MS, as the ADP-ribose 
can be lost during sample processing. Different strategies have focused on enrichment of the 
modified peptides, and gentle MS/MS methods have been optimized (Carter-O’Connell, Jin et 
al. 2014; Martello, Leutert et al. 2016). Mono-ADP-ribosyltransferases such as PARP10, 
unlike the poly-ADP-ribosyltransferases family members, have not been studied extensively 
and require further characterization.  
On the contrary to the TXNRD1 system, we expected the change in stability of substrates in 
both direction in the PARP10 system. The stability shift of several proteins known to interact 
with NAD verified the experiment quality. 28 potential protein substrates were found to change 
stability only when a combination of PARP10 and NAD was added to the lysate (16 stabilized 
and 12 destabilized proteins) (Figure 37A). Exemplary melting curves for these proteins are 
shown in Figure 37B. The OPLS-DA model was also capable of identifying these substrates 
by contrasting the Tm of “PARP10+NAD” Tm vs. those from all other treatments. Out of the 
28 identified putative substrates, 7 proteins mapped to “ribonucleoprotein complex” (p < 0.02), 
and 19 were localized to the “nucleus” (p < 0.05), which is in good agreement with the cellular 
roles and localization of PARP10 (Bock, Todorova et al. 2015). Several of these proteins such 
as ILF2 and 3 are already known substrates of PARP10 (Carter-O’Connell, Jin et al. 2016). 
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Figure 37. SIESTA identified known and novel protein substrates for PARP10. A) A Tm differences 
scatterplot reveals shifts occurring only upon simultaneous addition of NAD and PARP10 to the cell lysate. Red 
circles represent potential substrates melting reproducibly. B) Exemplary melting curves of putative PARP10 
substrates. C) Targeted MS/MS analysis of a RFK peptide showed the mono-ADP-ribosylation of a glutamic acid 
residue (the site with the highest sequence-fitting score). The fragments carrying the ADP-ribose are shown with 
an asterisk. D) HDAC2 mono-ADP-ribosylation was validated in two independent experiments using recombinant 
HDAC2 and two PARP10 catalytic subunit constructs (n=2 recpliates and mean±SD; *p<0.02 and **p<0.005 
two-sided student t-test). Figure reused with permission from (Saei, Astorga Wells et al. 2018). 
To validate a number of putative substrates, we manually checked their melting curves and 
extracted their rankings from OPLS-DA model loadings. Another criterion was the availability 
of high purity recombinant proteins. Finally, caspase-6 and RFK (stabilized) as well as PDRG1 
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and HDAC2 (destabilized) were chosen to verify the presence of PARP10-catalyzed mono-
ADP-ribosylation. These proteins were incubated with PARP10 and NAD, and then digested 
and analyzed by LC-MS/MS.  
The MS/MS events were monitored in real time for signature ions of adenine, adenosine-18 
and adenosine monophosphate (m/z 136.0623, 250.094 and 348.0709, respectively). The 
presence of these signatures would initiate a second MS/MS event using electron-transfer 
dissociation (ETD) with a supplementary HCD activation. Using this method, we could prove 
the mono-ADP-ribosylation of RFK on four sites Glu140, Glu131, Glu113 and Arg14 
(sequence coverage of 94%), ordered by the peptide score and PDRG1 on Glu110, Glu75 and 
Asp32 (sequence coverage of 74%). The ETD MS/MS spectrum of a RFK peptide (Glu140 
ADP-ribosylation) is shown in Figure 37C. Due to the incomplete sequence coverage of 
HDAC2 with trypsin (with and without LysC) digestion, an in vitro chemiluminescence assay 
was used for validation of mono-ADP-ribosylation on HDAC2. HDAC2 was significantly 
modified with both PARP10 catalytic domain constructs (Figure 37D). 
Although caspase-6 exhibited the largest specific stabilization (10.4 °C, Figure 37A-B) as 
a putative substrate for PARP10, we could not verify its modification in the two in vitro 
assays. A review of literature showed that PARP10 is actually a substrate for 
caspase-6 during apoptosis (Herzog, Hartkamp et al. 2013), having a major cleavage site 
for this protease at D406 (Herzog, Hartkamp et al. 2013). Therefore, the huge thermal shift 
specifically observed for caspase 6 might be related to induction of a conformational 
change in caspas-6 upon PARP10 binding. The conformational change in caspase-6 when 
binding to its substrates has been reported before (Vaidya, Velázquez-Delgado et al. 
2011). However, the auto-modification of PARP10 is required for effective binding, 
as a thermal stability shift for caspase-6 was not noted in the absence of NAD.  
Conclusions 
Based on the above results, we believe that SIESTA can be used as a universal approach for 
unbiased identification of protein substrates for specific enzymes in a proteome-wide manner. 
SIESTA can also be applied to discover cell- or tissue-specific substrates by comparative 
stability monitoring of lysates from different sources. Therefore, SIESTA is likely to enhance 
our understanding of enzyme systems in hemostasis and disease and facilitate the incorporation 
of substrates in high throughput screening in drug discovery and development. 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
In the past decade, proteomics-based target deconvolution technologies have evolved to 
system-wide methods in which all human proteins are scrutinized for binding or correlation 
with efficacy of unmodified compounds in living cells. The availability and evolution of several 
techniques for drug target and MOA characterization indicates that a single method is not 
capable of –or should not be trusted to, exclusively pinpointing the efficacy targets responsible 
for the compound effects. Although the readout from each technique is a list of potential targets, 
a long list of candidate protein can also confound the identification of central efficacy targets. 
Combining different methods allows for shortlisting the highly potential candidates. 
The inclusion of matrix-detached cells in the proteomics experiments such as FITExP was 
against the mainstream, but showed that specific information about drug targets, survival 
pathways and processes differentiating life from death can be obtained. We believe that this 
research will have an impact in later works and contribute to our understanding of cell death.   
ProTargetMiner is a resource for catering to the research community and for assisting the 
phenotypic drug discovery paradigm. This database can also open up an opportunity for reverse 
chemical proteomics for even linking known targets to novel biological phenomena by 
interpretation of compound-induced phenotypes, which can prove valuable in drug 
repurposing. ProTargetMiner can be expanded in future by profiling more cell lines, more 
drugs (also non-anticancer agents) and different biological concentrations. 
The protein pairwise correlation database based on ProTargetMiner dataset uncovered 
unexpected complexity in protein regulation that might not be an artefact. It is yet to be seen if 
this database can be used for characterization of proteins and their functions. Furthermore, the 
pairwise protein anti-correlation might reveal novel regulatory pathways, especially in the 
context of cancer. The set of proteins with most stable expression in ProTargetMiner is also a 
resource which must be analyzed in more detail to shortlist a number of top candidates with 
lowest standard deviation, high abundance and consistent expression in tissues. This goal can 
be partly achieved with the deep data available in MCF-7 and RKO cell lines in 
ProTargetMiner. 
Finally, the lack of knowledge on specific protein substrates for enzymes hampers the design 
of high-throughput screening assays in drug discovery. Furthermore, such knowledge in 
fundamental in the understanding of biology in homeostasis and disease. So far, we 
have demonstrated the application of SIESTA in the reactions involving electron transfer
(TXNRD1 system) and ADP-ribosylation. We also have positive results that SIESTA can 
be applied to identify phosphorylation events (in the AKT1 system) driving protein 
stability. Furthermore, SIESTA can be applied to different cell lines and tissues to 
discover cell- or tissue-specific PTMs. Another focus could be on delineating the 
isoform specificity in enzyme families (Gonzalez and McGraw 2009). Elucidation of 
substrate specificity is the key to targeted therapy (Toker 2012).
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